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Prolactinomas account for approximately 40% of all pituitary
adenomas and are an important cause of hypogonadism and
infertility. The ultimate goal of therapy for prolactinomas is
restoration or achievement of eugonadism through the nor-
malization of hyperprolactinemia and control of tumor mass.
Medical therapywith dopamine agonists is highly effective in
the majority of cases and represents the mainstay of therapy.
Recent data indicating successful withdrawal of these agents
in a subset of patients challenge the previously held concept
that medical therapy is a lifelong requirement. Complicated
situations, such as those encountered in resistance to dopa-
mine agonists, pregnancy, and giant or malignant prolacti-
nomas, may require multimodal therapy involving surgery,
radiotherapy, or both. Progress in elucidating the mecha-
nisms underlying the pathogenesis of prolactinomas may en-
able future development of novel molecular therapies for
treatment-resistant cases. This review provides a critical
analysis of the efficacy and safety of the various modes of
therapy available for the treatment of patients with prolacti-
nomas with an emphasis on challenging situations, a discus-
sion of the data regardingwithdrawal ofmedical therapy, and
a foreshadowing of novel approaches to therapy that may
become available in the future. (Endocrine Reviews 27:
485–534, 2006)
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I. Introduction
A. Historical overview
IN THE LATE 1920s and early 1930s, a number of groupsfound that pituitary extracts could induce milk secretion.
Riddle et al. (1–3) found that this substance, which they
named prolactin (PRL), was different from other known
growth- and gonadal-stimulating substances. They found
that this PRL stimulated production of a milk-like substance
from the crop sacs of pigeons and doves, and they developed
the pigeon crop sac assay (1–3) that became the standard
assay procedure for PRL over the next 30 yr. Eventually, this
assay was replaced by specific RIAs in a number of species.
In humans, however, because of the high lactogenic ac-
tivity of even very highly purified preparations of human
GH (4, 5), it was impossible to separate human PRL from GH
using the relatively crude pigeon crop assay, and the very
existence of a distinct PRL isoform in humans was ques-
tioned (5). On the other hand, at the same time, it was ob-
served that most patients with pituitary tumors in whom
galactorrhea and amenorrhea were the cardinal clinical fea-
tures did not have acromegalic features (6) and patients who
were known to have isolated, congenital GH deficiency were
able to lactate postpartum (7). In 1970, Frantz and Kleinberg
(8) developed a sensitive bioassay in which they used excess
antibody to GH to neutralize any potential lactogenic effects
it had and, for the first time, were able to demonstrate mea-
surable PRL levels in women with puerperal and nonpuer-
peral galactorrhea but not in most normal men. Subse-
quently, further purification of human PRL led to the
development of RIAs that could finally measure PRL levels
in the sera of normal individuals (9).
At the same time that PRL was initially being characterized
in the early 1930s by Riddle et al. (1–3), so too were appearing
the first clinical reports of a syndrome of amenorrhea cou-
pled with galactorrhea (10, 11). Over the ensuing 20 yr, three
distinct clinical syndromes were described: 1) the Chiari-
Frommel Syndrome—amenorrhea, galactorrhea, and low
urinary gonadotropins occurring postpartum (12); 2) the
Ahumada-Argonz-del Castillo syndrome—nonpuerperal
amenorrhea, galactorrhea, and low urinary gonadotropins
with no evidence of a pituitary tumor on standard skull
x-rays (13); and 3) the Forbes-Henneman-Griswold-Albright
syndrome—nonpuerperal amenorrhea, galactorrhea, and
low urinary gonadotropins in association with a chromo-
phobe adenoma (6). Overproduction of PRL was postulated
in both of the last two syndromes (6, 13). Friesen et al. (14)
then demonstrated elevated radioimmunoassayable PRL
levels in the serum of a patient with a prolactinoma, the fall
in such levels with partial tumor resection, and the produc-
tion of PRL by the tumor in vitro. The now recognized in-
sensitivity of standard skull x-rays and a better understand-
ing of the pathophysiology of prolactinomas have rendered
obsolete this early eponymic classification of PRL disorders.
B. Epidemiology
Prolactinomas are the most frequent pituitary tumors,
with an estimated prevalence in the adult population of 100
per million population (15). However, recently Beckers et al.
(16) found a much higher prevalence at 55 per 71,000 (775 per
million) inhabitants in Belgium. Their frequency varies with
age and sex, occurring most frequently in females between
20 and 50 yr old, when the ratio between the sexes is esti-
mated to be 10:1. After the fifth decade of life, the frequency
of prolactinomas is similar in both sexes (17, 18). In the
pediatric/adolescent age, prolactinomas are rare, but repre-
sent about half of all pituitary adenomas, which, overall,
account for less than 2% of intracranial tumors (19, 20). One
possible explanation for the increased prevalence of prolacti-
nomas in women may be related to the fact that the clinical
presentation in women is more evident, usually the classical
amenorrhea-galactorrhea syndrome, whereas men may ig-
nore the symptoms of impotence and decreased libido and
the diagnosis is often made when signs of compression due
to the tumor develop (17). However, studies comparing the
clinical and pathological correlates of growth of these tumors
in both sexes are lacking, and a more aggressive course of the
disease in men has not been ruled out. Delgrange et al. (21)
showed a greater growth potential of macroprolactinomas in
men than in women as well as a male preponderance of
aggressive forms of the disease (i.e., giant, invasive, and
malignant prolactinomas).
Prolactinomas cause gonadal and sexual dysfunction re-
lated to the hyperprolactinemia and may cause other symp-
toms related to the tumor expansion. The major objectives of
treating patients with prolactinomas are: 1) to suppress ex-
cessive hormone secretion and its clinical consequences, such
as infertility, sexual dysfunction, and osteoporosis; 2) to con-
trol tumor mass, thereby relieving visual field defects, cranial
nerve function, and possibly hypopituitarism; 3) to preserve
or improve residual pituitary function; and 4) to prevent
disease recurrence or progression. Treatment goals for mi-
cro- and macroprolactinomas are similar; however, for the
majority of microprolactinomas, control of tumor size is a less
clinically important endpoint because microprolactinomas
do not cause neurological defects, nor are they at substantial
risk for growth over time. In larger macroprolactinomas that
are at risk for neurological sequelae, control of tumor growth
or reduction in size takes priority over the treatment of hy-
pogonadism. Furthermore, patients with macroprolactino-
mas and hypopituitarism should receive standard hormonal
replacement therapy for hypopituitarism as in other types of
macroadenomas. The initiation of GH replacement should be
delayed if there is a reasonable likelihood that hypopituitar-
ism will resolve and/or normoprolactinemia can be
achieved, because GH deficiency can resolve with pharma-
cotherapy-induced PRL normalization (22). If substantial tu-
mor reduction is not observed after initiating treatment for
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the prolactinoma and reversal of GH deficiency does not
appear realistic, GH therapy should be considered. Because
of a theoretical risk of GH/growth factor-induced tumor
enlargement, GH therapy in this situation must be done
cautiously.
This review provides a critical analysis of the efficacy and
safety of the various modes of therapy available for the
treatment of patients with prolactinomas. Special attention
will focus on challenging situations, including the treatment
of patients resistant to dopamine agonists, the treatment of
children and adolescents, and management of women who
become pregnant. We will review the evidence of the efficacy
of withdrawal from dopamine agonists after long-term treat-
ment and, finally, highlight experimental therapies currently
under investigation.
II. Observation
A. Treatment indications
Asymptomatic patients with prolactinomas do not have an
absolute requirement for treatment of their prolactinomas.
Indications for therapy in patients with prolactinomas may
be divided into two categories: 1) effects of tumor size, and
2) effects of hyperprolactinemia (Table 1). Studies examining
the natural history of untreated microprolactinomas have
shown that significant growth of these tumors is uncommon
(Table 2). Six series of patients with microadenomas who
were found to have computed tomography (CT) or tomo-
graphic evidence of prolactinomas were observed without
treatment for a period up to 8 yr (23–28). Of 139 women, only
nine (7%) microprolactinomas had evidence for growth.
Thus, the simple argument that therapy is indicated for a
microadenoma to prevent it from growing is fallacious. On
the other hand, an untreated prolactinoma should be fol-
lowed closely to determine whether it is enlarging. It is very
unlikely for a prolactinoma to grow significantly without an
increase in serum PRL levels, although this phenomenon has
been reported (29). Therefore, most patients with microad-
enomas verified by imaging may be monitored with serial
PRL levels. Although there is no consensus on the frequency
of imaging after the achievement of normoprolactinemia,
most clinicians monitor with pituitary magnetic resonance
imaging (MRI) periodically to verify the absence of tumor
growth and to ensure that PRL levels are reliable indicators
of tumor size. If PRL levels rise or symptoms of mass effects
develop (such as headaches), then repeat scanning is indi-
cated to evaluate for the possibility of significant tumor
growth. Significant increases in PRL levels usually, although
not always (30), reflect tumor growth. A microadenoma with
documented evidence of growth demands therapy for the
size change alone, because it may be one of the 7% that will
grow to be a macroadenoma.
The presence of a macroadenoma raises the probability for
the tumor in question to have biological characteristics that
confer a propensity to grow. Moreover, most macroprolacti-
nomas are associated with PRL elevations significant enough
to elicit symptoms that would warrant treatment. Therefore,
unless there are specific contraindications, therapy is usually
advisable for these tumors. Local or diffuse invasion and
compression of adjacent structures, such as the stalk or optic
chiasm, are additional indications for therapy.
Other indications for therapy are relative, being due to the
hyperprolactinemia itself. These include: decreased libido,
menstrual dysfunction, galactorrhea, infertility, hirsutism,
impotence, and premature osteoporosis. Eugonadal women
with nonbothersome galactorrhea do not have specific rea-
sons for therapy. On the other hand, a woman harboring a
prolactinoma with amenorrhea and anovulation who wishes
to become pregnant has a clear indication for therapy. How-
ever, if such a woman does not wish to become pregnant,
then therapy may be warranted to prevent osteoporosis or to
improve libido.
B. Oral contraceptives for hypogonadism
Hypogondal women with microprolactinomas may be
treated for their hypogonadism with oral contraceptives,
provided that their PRL levels do not increase substantially
and there is no evidence of tumor enlargement (31). Series of
patients with prolactinomas who are treated with oral con-
traceptives for hypogonadism have not shown substantial
risk for tumor enlargement (32). Individual case reports of
tumor enlargement during estrogen therapy have been doc-
umented, but whether tumor enlargement in these cases was
related to use of estrogen or reflected the natural progression
of these particular tumors is not known. Because of this
uncertainty, it is advisable to monitor patients who use oral
contraceptives carefully with periodic measurement of PRL
levels (33–35).
The ability to follow patients closely with PRL levels, MRI
scans, and bone mineral density (BMD) studies and the
knowledge of the efficacy of various modes of therapy allow
TABLE 2. Studies examining the natural history of
microprolactinomas
Study Ref. Patients(n)
Evidence of
tumor growth
Length of
follow-up
(yr)
Von Werder et al. 27 10 1 4
March et al. 24 43 2 4
Weiss et al. 28 27 3 6
Koppelman et al. 23 8 1 2.5–7.5
Sisam et al. 26 38 0 4
Schlechte et al. 25 13 2 5.3
TOTAL 139 9 (6.5%) 2.5–8.0
TABLE 1. Indications for therapy
Mass effects
Hypopituitarism
Visual field defects due to pressure on the optic chiasm
Cranial nerve deficits
Headaches
Effects of hyperprolactinemia
Hypogonadism
Amenorrhea or oligomenorrhea
Infertility
Impotence
Osteoporosis or osteopenia
Relative indications
Bothersome hirsutism
Bothersome galactorrhea
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a highly individualized way of managing patients and choos-
ing the proper mode of their therapy.
III. Surgery
A. Surgical approaches
Historically, surgical resection of prolactinomas was the
preferred mode of therapy until the mid-1980s, when bro-
mocriptine became available and was shown to be effective
in the control of these tumors. Most, although not all, au-
thorities reserve surgical treatment of prolactinomas for spe-
cial circumstances. A list of surgical indications is presented
in Table 3.
Pituitary apoplexy is a potentially life-threatening clinical
syndrome caused by infarction or hemorrhage into an ex-
isting pituitary tumor (36). These patients may develop vi-
sual disturbance, associated with severe headache, altered
consciousness, and vascular collapse. Under certain circum-
stances, i.e., severe, progressive visual loss, it represents the
most urgent indication for surgical intervention. There is
solid evidence, however, that apoplexy in patients with sta-
ble visual field deficits may be managed medically under
careful monitoring, with complete resolution of neurooph-
thalmological signs and visual deficits (37–39). An effort to
manage patients with pituitary apoplexy nonsurgically is
particularly important for prolactinomas, because surgical
intervention and decompression do not ensure long-term
cure of these tumors. Neurosurgical and endocrine expertise
is required to safely manage and monitor patients with ap-
oplexy nonsurgically. Other indications include failure of
medical therapy, defined as inadequate PRL reduction on
high doses of dopamine agonists, or tumor enlargement,
even if accompanied by sufficient PRL lowering. Finally,
surgery may be necessary in pregnant women with expand-
ing prolactinomas associated with unstable neuroophthal-
mological deficits that do not respond to bromocriptine (see
Section IX).
When surgery is undertaken, the transsphenoidal ap-
proach represents the standard of care for microprolactino-
mas and the overwhelming majority of macroprolactinomas
(40). Craniotomy, which is rarely indicated, is reserved for
tumors that are inaccessible via the transsphenoidal ap-
proach. Such cases might include patients with large tumors
with suprasellar, parasellar, or unusual intracranial exten-
sions, such as those extending toward the frontal or temporal
lobes (41). Favorable experience with variations of the stan-
dard transsphenoidal approach have recently been described
and provide alternatives to transcranial approaches, even for
previously unapproachable lesions involving the cavernous
sinus and parasellar region (42). Giant and invasive prolacti-
nomas cannot be cured by surgery, regardless of the surgical
technique employed or the experience of the neurosurgeon;
therefore, if undertaken, the goal of surgery under these
circumstances is to debulk with the prospect of improving
symptoms related to mass effects (43).
B. Endoscopy
Recent technological advances have catapulted minimally
invasive endoscopic techniques to the forefront of transsphe-
noidal surgery (41). The main advantage afforded by endos-
copy is the superior panoramic view. Some surgeons exploit
endoscopy as an adjunctive visualizing tool, but increas-
ingly, the endoscope is being used as a stand-alone operating
instrument, used in one of several different ways. The most
common method consists of an endoscopic endonasal uni-
lateral approach, permitting removal of the entire tumor
through the nostril. In addition to the wide surgical view,
endoscopy provides three additional potential benefits, in-
cluding: 1) avoidance of submucosal transseptal dissection,
thus eliminating nasoseptal perforations; 2) less patient dis-
comfort due to the lack of nasal packing; and 3) reduced
operative time and hospital stay (44). For the neurosurgeon,
the major obstacle to adopting the endoscopic technique is
that of the need to acquire novel surgical skills (45, 46).
Although the number of reported cases and follow-up du-
ration are limited, preliminary studies suggest that compli-
cation rates of the endonasal endoscopic approach may be
comparable to, or perhaps slightly lower than, those ob-
served using the traditional operating microscope (47–51).
Two studies comparing outcomes of endonasal endoscopic
microsurgery and sublabial microsurgery specifically for
prolactinomas found no differences in initial surgical remis-
sion rates but fewer minor complications associated with
endoscopic or endoscopic-assisted procedures (52, 53).
C. Intraoperative imaging
Currently, intraoperative imaging is used by most neuro-
surgical centers, both for guidance to reach the sphenoid
sinus and sella and to assess the extent of tumor resection.
C-arm videofluoroscopy is the most widely used guidance
device. Frameless stereotaxy, or “neuronavigation”, is a
newer intraoperative computer-guided imaging system that
assists the surgeon in the identification of anatomical land-
marks and allows referral to preoperative MRI images in
several planes of view simultaneously. This technique is
achieved by segmentation and three-dimensional recon-
struction of the tumor and adjacent structures. Neuronavi-
gation is most valuable in reoperations where the anatomy
may be distorted, but it is also helpful in surgeries involving
large, invasive or suprasellar tumors and in cases where the
carotid arteries are closely approximated or kinked (40, 54).
Because the morphology of the tumor and neurovascular
structures shift during tumor resection, frameless stereotaxy
cannot be used to estimate the extent of tumor removal.
TABLE 3. Indications for surgery
Unstable pituitary apoplexy
Failure of medical therapy
Inadequate reduction of PRL to restore gonadal function
Tumor enlargement
Tumor enlargement despite sufficient PRL reduction
Desire for pregnancy
Previous pregnancy complicated by symptomatic tumor
expansion
Personal choice to avoid dopamine agonist therapy during
estation (macroadenomas)
Symptomatic, unstable tumor enlargement during pregnancy that
does not respond to reinstitution of dopamine agonist treatment
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Moreover, these systems have the disadvantage of requiring
greater set-up time. Whether the use of neuronavigational
systems improves surgical cure rates or reduces the fre-
quency of complications is unknown.
Intraoperative MRI has been used in some centers to de-
lineate tumor borders and to accurately monitor the extent of
tumor resection (55). This imaging modality is in an evolving
stage of development and improvement. A comprehensive
evaluation of the different available MRI systems has been
reported by Albayrak et al. (55). The predominant opinion is
that intraoperative MRI will have limited use in resecting
purely sellar microadenomas but may be beneficial for as-
sessing the adequacy of resection of supra- and parasellar
extensions (40). Long-term results are not available to de-
termine whether this application improves surgical
outcomes.
Use of ultrasonography is chiefly used in transcranial pro-
cedures performed in the resection of giant macroadenomas.
The advantage of ultrasound over MRI is the provision of
real-time feedback to the surgeon during tumor removal.
Because indications to resect giant invasive prolactinomas
requiring craniotomy are extraordinarily rare, this imaging
modality, in its current form, is suspected to have limited
application for the surgical management of prolactinomas.
Regardless of the innovative operative techniques and im-
aging modalities emerging, the specific surgical treatment
plan of a patient with a prolactinoma ultimately depends
upon the availability, familiarity, and expertise of these in-
struments for the neurosurgical center and neurosurgeon to
which one refers their patients. Definitive data on the impact
of these advances on surgical outcomes are not yet available.
D. Surgical success rates
Surgical outcomes are highly dependent upon the exper-
tise and experience of the neurosurgeon, as well as the size
of the tumor. Surgical results from 50 published series are
summarized in Table 4. Only results from the latest series
from a given neurosurgical/endocrine team are included,
omitting data from earlier studies. Criteria for inclusion in
this analysis consists of the following: 1) cure or remission
rates are reported with respect to size of the tumor (microad-
enoma vs. macroadenoma); 2) normalization of PRL levels
defines surgical remission; and 3) surgical cure rates are
reported on the basis of the number of patients with docu-
mented follow-up. Combining data from all 50 series, 1596
of 2137 (74.7%) microadenomas and 755 of 2226 (33.9%)
macroadenomas were classified as achieving initial surgical
remission, i.e., having PRL levels normalized by 1–12 wk
after surgery. Within these series, the surgical success rates
were highly variable. For series with at least 10 patients, the
surgical remission rate varied from 38 to 100% for microad-
enomas and from 6.7 to 80% for macroadenomas. Similar
data were obtained from a mail survey of 80 neurosurgeons,
which found surgical cure rates of 74% of 1518 PRL-secreting
microadenomas and 30% of 1022 PRL-secreting macroad-
enomas (56). In this latter report, criteria for the assign-
ment of patients to micro- or macroadenoma status was
made on the basis of imaging and/or PRL levels ( or 
200 ng/ml, respectively). Clearly, for the macroadenomas
the success rate in large part was dependent on the size of
tumors chosen for surgery. In many series, the objective
was, appropriately, debulking of a very large tumor rather
than cure, and in other series very large tumors were not
operated upon.
Although surgical series reported from the last decade
have used some of the newer techniques described above, the
results from these series cannot be strictly compared with
those of early series because of differences in the patient
populations. In the past 10–15 yr, most patients were treated
with dopamine agonists first, and only those resistant to or
intolerant of these drugs or whose tumors did not decrease
in size were referred for surgery. In some series, it was
reported that prior use of dopamine agonists made it more
difficult to remove the tumor (see Section III.E for a more
extensive discussion of this). Overall, it does not appear that
surgical outcomes are substantially different now compared
with 20 yr ago, but a formal analysis cannot be carried out
for the above-stated reasons.
In a number of series, it was the impression that PRL levels
were more predictive of surgical success than actual size of
the tumor. Patients with serum PRL levels above 200 ng/ml
were found to have a decreased chance for cure at surgery
even when stratified within micro- and macroadenoma
groups (57–62). Thus, PRL levels above 200 ng/ml appear to
be a risk factor for poor surgical outcome independent of
tumor size. An obvious explanation for this finding is lack-
ing, because one would expect higher PRL levels in more
highly differentiated tumors, which might thereby impart a
greater likelihood of complete tumor resection. It is unknown
whether the extent of dural invasion and the degree of his-
tological differentiation of a tumor correlate with PRL levels
in prolactinomas.
Gonadal function is almost uniformly restored in both
sexes upon achievement of normoprolactinemia after suc-
cessful surgical resection (63–66). In young women, normal
LH pulsatility is restored as early as the eighth postoperative
day (66, 67). Often normal reproductive function is obtained
even with PRL levels slightly above normal, but because such
patients appear to have a much greater chance of recurrence
of more significant hyperprolactinemia (see Section III.F),
they cannot be deemed definitively cured. Patients with mac-
roadenomas of all types may be hypopituitary before surgery
and, because of the extent of surgery sometimes performed,
may have significant changes in pituitary function postop-
eratively. In an analysis of 84 patients with macroadenomas
(36 were prolactinomas), Nelson et al. (68) found that of those
with normal preoperative pituitary function, only 78% re-
tained normal function postoperatively. One third with some
pituitary deficits before surgery improved, and one third
with such deficits had worsened pituitary function after sur-
gery. None of the panhypopituitary patients improved after
surgery (68).
E. Recurrence and long-term cure
One of the most controversial areas regarding the surgical
management of prolactinomas involves the likelihood of a
recurrence of hyperprolactinemia in patients who have un-
dergone an initial remission. Rates of recurrence, as observed
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with rates of surgical remissions, are highly variable among
neurosurgical centers, ranging from 0 (69) to 50% (70). In
part, this reflects differences in the level of neurosurgical
expertise. Unfortunately, the surgical literature is con-
founded by variable follow-up times, drop-out rates, and
definitions of cure/recurrence. It is possible, and even likely,
that surgical series with relatively short follow-up times will
underestimate the true recurrence rate because the time to
recurrence of hyperprolactinemia in some tumors may be
lengthy (71). As for surgical cure, most often, recurrence is
defined as the discovery of an elevated PRL level at any point
in the postoperative surveillance period after an initial sur-
gical remission. On the other hand, some authors use less
stringent criteria, regarding patients with mild asymptom-
atic hyperprolactinemia as in remission (72). Given all of
these factors, a true assessment of recurrence rates is difficult
to establish.
Adding further confusion to the controversy are series
reporting that recurrence of mild hyperprolactinemia in
some women after adenomectomy for prolactinomas re-
solves with time, and therefore may not definitively reflect
operative failure (73, 74). One important study described the
TABLE 4. Surgical outcomes for prolactinomas
Tumors operated Tumors inremission % in remission Recurrence % Recurrence
First author of series Ref. Micro Macro Micro Macro Micro Macro Micro Macro Micro Macro
Antunes 114 9 8 3 3 33.3 37.5
Wiebe 62 13 5 38.5
Aubourg 578 23 67 13 26 56.5 38.8
Domingue 433 67 25 46 10 68.7 40.0
Grisoli 436 20 6 30.0
Nicola 579 70 40 47 16 67.1 40.0
Rawe 61 21 9 17 3 81.0 33.3
Samaan 580 26 20 76.9
Landolt 59 33 37 25 10 75.8 27.0
Pelkonen 438 6 53 3 6 50.0 11.3
Tucker 581 27 18 20 8 74.1 44.4 3 15.0
Faria 582 72 28 55 13 76.4 46.4 4 4 13.3 36.4
Giovanellia 583 48 38 79.2 10 26.3
Smallridge 584 19 5 12 0 63.2 0.0
Von Werder 27 31 20 64.5
Woosley 585 22 14 16 5 72.7 35.7 1 0 6.3 0.0
Ciric 465 41 11 26.8
Nelson 586 28 11 21 4 75.0 36.4 8 1 38.1 25.0
Randall 60 54 46 39 13 72.2 28.3
Dupuy 434 2 78 2 7 100.0 9.0
Hardy 75 186 89 143 34 76.9 38.2 12 4 50.0 80.0
Rodman 587 42 23 37 9 88.1 39.1 5 1 17.2 20.0
Brabant 588 19 37 11 14 57.9 37.8
Charpentier 57 58 289 35 134 60.3 46.4 2 10 5.7 7.5
Fahlbusch 58 108 139 66 15 61.1 10.8 8 1 16.0 6.7
Scanlon 69 15 20 10 16 66.7 80.0 0 0 0.0 0.0
Arafah 589 74 46 67 29 90.5 63.0 5 10 7.5 34.5
Parl 590 13 11 4 10 30.8 90.9
Schlechte 336 30 24 20 11 66.7 45.8 8 4 40.0 36.4
Bevan 85 39 28 27 8 69.2 28.6 1 1 3.7 12.5
Guidetti 466 34 120 20 11 58.8 9.2 8 4 40.0 36.4
Ciccarelli 71 18 4 4 4 22.2 100.0
Webster 80 42 37 35 28 83.3 75.7 6 2 17.1 7.1
van’t Verlaat 591 11 11 100.0 5 45.5
Thomson 592 61 8 46 4 75.4 50.0 8 0 19.5 0.0
Massoud 73 64 58 90.6 25 43.1
Soule 593 11 23 5 4 45.5 17.4 1 0 20.0
Giovanellia 88 92 118 71 26 77.2 22.0
Biller 594 23 14 21 6 91.3 42.9 2 9.5 0.0
Inoue 133 13 7 53.8
Turner 92 32 25 78.1 1 4.0
Tyrrell 72 84 129 69 83 82.1 64.3
Gokalp 76 311 239 200 16 64.3 6.7
Acquati 595 83 15 18.1 2 13.3
Abe 596 5 9 4 2 80.0 22.2
Amar 82 107 115 97 79 90.7 68.7 0 41 0.0 51.9
Kristof 79 5 32 2 8 40.0 25.0 1 1 50.0 12.5
Wolfsberger 81 11 9 81.8 1 11.1
Esposito 597 20 22 15 6 75.0 27.3 5 0 33.3 0.0
Mortini 598 69 82 52 41 75.4 50.0 9 6 17.3 14.6
Totals 2137 2226 1596 755 74.7 33.9 147 106
a These appear to be separate series of patients.
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course of eight patients who developed recurrent hyperp-
rolactinemia 2 to 10 yr postoperatively and who were mon-
itored thereafter without treatment (74). One patient was
found to have primary hypothyroidism and became normo-
prolactinemic with l-T4 therapy, thus accounting for her PRL
elevation. Of the remaining seven patients, four underwent
a spontaneous remission of hyperprolactinemia. This course
of relapse, followed by a second remission, has not been
widely reported. It is unknown whether these experiences
are atypical or whether they reflect a more frequent outcome
that has simply gone unrecognized thus far.
From the series compiled in Table 4, recurrence rates for
microadenomas [147 of 809 (18.2%)] and macroadenomas
[106 of 465 (22.8%)] are similar. It should be emphasized that
under most circumstances, the recurrence is detected bio-
chemically (hyperprolactinemia), not necessarily with radio-
graphic documentation of tumor regrowth. Recurrence of the
hyperprolactinemia is usually accompanied by sexual/re-
productive dysfunction, which thereby serves as an indica-
tion for medical therapy to reduce PRL hypersecretion. In a
series of patients with microadenomas operated upon by Dr.
Jules Hardy, of 58 patients with a normal PRL postopera-
tively, 25 had a relapse of hyperprolactinemia after a mean
of 3.3 yr, but only 10 of these 25 had a recurrence of amen-
orrhea or galactorrhea, and CT scans showed evidence of a
recurrence of the microadenoma in only two (75).
Overall long-term surgical cure rates may be calculated
based upon series that have reported both initial remission
rates and recurrence rates, understanding that these num-
bers reflect somewhat of a reporting bias, because they are
derived from neurosurgeons who are willing to publish their
data. Based on the initial remission rate of 74.7% and the
recurrence rate of 18.2% cited above, an overall long-term
surgical cure rate for microadenomas among these selected
series, using a normal PRL level as the criterion, is 61.1%. For
patients with macroadenomas, with an initial remission rate
of 33.9% and a recurrence rate of 22.8%, the long-term cure
rate is 26.2%. These general numbers may be given to pa-
tients when counseling them with respect to choices of ther-
apy. Neurosurgeons who have compiled their own data on
surgical cures and remission may provide patients with more
meaningful personal estimates for cure, based upon their
individual statistics. For patients with giant prolactinomas
and those with considerable cavernous sinus invasion, the
chance for surgical cure is essentially zero (76–78).
F. Predictors of remission and cure
A number of studies have analyzed factors that might
predict initial surgical remission and likelihood for long-
term cure. As discussed above, several studies have identi-
fied an inverse relationship between preoperative PRL levels
and chances for initial surgical remission (57, 60–62, 72,
79–81). Initial surgical success is also correlated with ade-
noma stage (58, 72). A low immediate postoperative PRL
level has been shown to be an excellent predictor of long-
term surgical cure (82, 83). For example, one large analysis
of surgical outcomes of 339 surgically resected prolactinomas
showed that when a postoperative PRL level below 5 ng/ml
was achieved, 80.5% of the cohort remained in remission
over a mean follow-up of 9.2 yr (83).1 In this series, the
immediate postoperative PRL level was a better predictor of
long-term surgical cure than the preoperative PRL level. A
separate (5-yr follow-up) study found that a postoperative
PRL below 10 ng/ml predicted biochemical cure with 100%
accuracy for both micro- and macroadenomas; cure was un-
likely to be obtained in patients with postoperative PRL
levels between 10 and 20 ng/ml (i.e., the high normal range)
(82). Repeat transsphenoidal surgery for persistent tumor
after failed surgery or radiotherapy is curative in less than
50% of the cases (83).
An extensive debate regarding the effects of pretreatment
with dopamine agonists on surgical outcomes for prolacti-
nomas has pervaded the surgical literature in the past.
Landolt et al. (84) were the first to report better surgical cure
rates for microadenomas that had not been exposed to do-
pamine agonists before surgery. In the hands of some neu-
rosurgeons, it is the impression that dopamine agonist treat-
ment induces tumor fibrosis, creating a tough tumor
consistency that made surgical removal difficult. However,
the majority of other series investigating this issue have not
corroborated these results (72, 85–89). Because surgery for
prolactinomas in the present era most often follows a trial of
dopamine agonist therapy, the decision of whether or not to
use a dopamine agonist has already been made.
G. Complications
Complications from transsphenoidal surgery for microad-
enomas are quite infrequent, the mortality rate being at most
0.6%, the major morbidity rate being about 3.4% (visual loss
0.1%, stroke/vascular injury 0.2%, meningitis/abscess 0.1%
and oculomotor palsy 0.1%) and cerebrospinal fluid (CSF)
rhinorrhea occurring in 1.9% (41, 56, 90, 91). The mortality
rate for transsphenoidal surgery for all types of secreting and
nonsecreting macroadenomas is 0.9%, the major morbidity
rate is 6.5% (visual loss 1.5%, stroke/vascular injury 0.6%,
meningitis/abscess 0.5%, and oculomotor palsy 0.6%), and
the rate of CSF rhinorrhea is 3.3% (41, 56, 90, 91). Transient
diabetes insipidus is quite common with transsphenoidal
surgery for both micro- and macroadenomas, and permanent
diabetes insipidus occurs in about 1% of surgeries on mac-
roadenomas (56, 91). Hypopituitarism is common in patients
with macroadenomas before surgery as a result of mass
effects, occurring in more than 50% of patients. With surgery,
either further worsening or improvement may occur (68).
GH deficiency after transsphenoidal surgery for micropro-
lactinomas was reported as high as 30% in one series (92).
Surgery involving craniotomy is much more hazardous. Al-
though visual field defects and reduction in visual acuity can
be improved in 74% of patients whose macroadenomas abut
the optic chiasm (93), a small number of patients with normal
visual fields may have a reduction of vision after surgery due
to herniation of the chiasm into an empty sella, direct injury
or devascularization of the optic apparatus, fracture of the
orbit, postoperative hematoma, or cerebral vasospasm (94).
1 These data were not incorporated into the present analysis of sur-
gical remission and recurrence rates because percentages of cure were
reported based on the number of individuals in the initial cohort, rather
than on patients who truly followed up.
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H. Surgical vs. medical therapy
Although most authorities recommend transsphenoidal
surgery as a second line option for prolactinomas, some
experts continue to advocate surgery as a potentially curative
procedure in selected patients (72, 92, 95, 96). These experts
propose that young patients with microadenomas who have
a good chance of cure could avoid the need for extended
medical therapy. Enthusiasm for this perspective is tempered
by recent evidence that withdrawal of cabergoline may lead
to sustained remission in some cases (97, 98). Couldwell and
Weiss (99) make an economic argument that surgical inter-
vention is less expensive than lifelong medical therapy. On
the other hand, a surgery complicated by hypopituitarism
has the potential to incur significantly higher costs (with
replacement of pituitary hormones) and lead to higher mor-
bidity (secondary adrenal insufficiency) over many years.
Admittedly, hypopituitarism is an unlikely complication for
the resection of a microprolactinoma in the hands of an
experienced neurosurgeon. One should also bear in mind
that with the expected upcoming availability of cabergoline
in generic form, even an uncomplicated transsphenoidal sur-
gery may prove to be more expensive than the cost of medical
therapy. Given its efficacy and safety, as discussed in Section
V, medical therapy remains the first line therapy for the
treatment of prolactinomas.
IV. Radiotherapy
A. Delivery of radiotherapy
The availability of highly effective medical and surgical
therapies for the majority of prolactinomas has rendered the
role of radiotherapy in the management of prolactinomas as
one of adjunctive therapy. In most cases, radiotherapy is
used after failed transsphenoidal surgery and medical ther-
apy. Rarely, in a few centers, it has been administered post-
operatively as a prophylactic measure to prevent growth of
a remnant tumor.
Today, several methodologies for the delivery of radio-
therapy are available. Conventional fractionated external
beam radiotherapy involves the use of several ports to con-
centrate an x-ray beam on the pituitary fossa by a crossfire
technique while the patient is immobilized in an individually
shaped plastic mask. Supravoltage radiotherapy is delivered
in daily doses of 200 cGy 4–5 d/wk over a period of 5–6 wk
up to a total dose of 4500–5000 Gy (100). Stereotactic con-
formal radiotherapy (SCRT) is also a fractionated form of
radiotherapy, but uses stereotactic techniques to deliver ra-
diation with higher precision. The underlying principle of
SCRT is to shape the radiation beams to conform to the shape
of the tumor, thereby reducing radiation exposure to sur-
rounding normal brain (101). Most SCRT is delivered with
linear accelerators (LINAC) that generate photon beams fo-
cusing on a stationary target, using a moving gantry system
(102). Most recently, single dose radiotherapy has become
widely available and is being increasingly used. This form of
radiotherapy delivers a necrotizing dose to the tumor, which
has been stereotactically defined using three-dimensional
image processing. The hallmark of this type of radiotherapy
is the sharp dose gradient of radiation at the treatment field
edges, which reduces the dose of radiation to the surround-
ing normal brain tissue. Most single-dose radiotherapy uses
cobalt-60 gamma radiation emitting sources (“gamma-knife”
radiotherapy) arranged in a hemisphere to focus on a central
target. This results in multiple small radiation spheres that
are combined in a multiple isocenter technique to conform to
the shape of nonspherical pituitary tumors (103). An alter-
native method of delivering single-dose radiation therapy is
with the use of a LINAC-based system that has been mod-
ified to limit mechanical instability and inaccuracy (104, 105).
There is no clear advantage for either of these single-dose
techniques (gamma knife vs., LINAC) in terms of their ability
to spare normal tissue from high radiation doses (106). Treat-
ment of pituitary adenomas with single-dose radiation ther-
apy using heavy-charge particle proton beams is very lim-
ited, because few centers have the facilities to provide this
form of radiotherapy, due to its high operational and main-
tenance costs (107). As of yet, there are no adequate studies
to conclude whether there is one mode of single dose radio-
therapy that has superior efficacy or safety.
Regardless of the delivery system, the aim of all high
precision techniques is to minimize radiation exposure to the
surrounding normal tissue. The combination of better im-
mobilization and high-definition three-dimensional imaging
has been the most important determinant of improvements
in modern radiotherapy—less so the technique of delivery
(103). The two general therapeutic goals for performing ra-
diotherapy in prolactinomas are: 1) arrest of tumor growth
and prevention of further problems from mass effects; and 2)
normalization of hyperprolactinemia (108–112). However, it
is possible that persistent postradiotherapy elevations of PRL
in patients with prolactinomas are due to a radiation effect
and are not caused by hypersecretion from residual tumor
(113). Although these arguments may hold true, the variable
definitions of “mildly elevated PRL levels” and “improve-
ment” preclude an accurate assessment of radiotherapy
efficacy.
B. Analysis of radiotherapy studies
There are several important caveats regarding the critical
interpretation of data in clinical studies of the efficacy of
radiotherapy for the treatment of prolactinomas. The first
relates to the definitions of tumor control endpoints. Tumor
control may be defined with either endocrinological (nor-
malization of PRL levels) or volumetric (long-term radio-
graphic assessment of tumor size) parameters. Many series
report a tumor “control” rate, which often refers to the stable
PRL levels or the absence of radiographic progression. More-
over, many of the series do not report the mean or median
duration of follow-up. Under these circumstances, the data
do not provide an appropriate measure of efficacy. The sec-
ond important observation is that the majority of the studies
are retrospective, single-arm analyses. Few of them report
the rate of decline of PRL. Finally, and most importantly,
many of the studies are confounded by the inclusion of
patients who were receiving concomitant medical therapy. A
number of patients in whom cure was reported continued to
require dopamine agonist therapy. Therefore, in some cases,
492 Endocrine Reviews, August 2006, 27(5):485–534 Gillam et al. • Treatment of Prolactinomas
it is impossible to separate out any PRL-lowering effects of
radiotherapy from the effects of dopamine agonists. In the
present review, we have chosen to confine the analysis to the
normalization of hyperprolactinemia. It should nevertheless
be acknowledged that in many cases the goal of radiotherapy
for treatment-resistant tumors was control of growth or al-
leviation of mass effects. To accurately assess the efficacy of
radiotherapy for these situations, standard criteria for
growth control would be necessary.
C. Efficacy—conventional radiotherapy
Approximately 250 patients have been reported who have
undergone treatment with conventional radiotherapy alone,
or after failure of medical and/or surgical therapy (114–126).
In all of these settings, normalization of hyperprolactinemia
was infrequent, with an overall normalization rate for the
entire series of 34.1%. When normal PRL levels were
achieved, it was only with an extended latency in most cases.
Conventional radiotherapy after noncurative surgery
rarely normalizes PRL levels. A total of three studies report
PRL normalization rates of 1 of 11 (9%) (119), 0 of 11 (0%)
(115), and 3 of 13 (23%) (121) when radiotherapy was ad-
ministered after incomplete surgical resection. Two series of
patients who received LINAC-based fractionated radiother-
apy after unsuccessful transsphenoidal surgery achieved
PRL normalization rates similar to those receiving conven-
tional fractionated radiotherapy (36.3 and 25%) (127, 128).
The remainder of the studies in this group included pa-
tients treated with a dopamine agonist or with all three
modalities (surgery, dopamine agonists, and radiotherapy).
Thus, it is uncertain what specific effect radiotherapy had in
PRL lowering, or normalization, in these patients. Because
these prolactinomas often represent the most therapy-resis-
tant tumors, normalization of hyperprolactinemia may not
have been feasible. Therefore, the rates of normalization are
expected to be poor. In many of these cases, the goal of
radiotherapy may have been to control further growth or to
relieve mass effects on cranial nerves.
D. Efficacy—single-dose stereotactic radiotherapy
Almost 300 patients (Table 5) have been reported who
have undergone treatment with single-dose stereotactic ra-
diotherapy alone, or after failure of medical and/or surgical
therapy (127, 129–149). In all of these settings, normalization
of hyperprolactinemia was infrequent, with an overall nor-
malization rate for the entire series of 31.4%. One could argue
that the short follow-up duration among these series may
have underestimated the complete response rate for these
tumors treated with single-dose radiotherapy.
Only one study reported the outcomes of patients treated
with single-dose stereotactic radiotherapy as primary ther-
apy for prolactinomas (146). Follow-up beyond 2 yr was
available for 77 patients who were not receiving bromocrip-
tine. Normalization of PRL in the absence of concomitant
medical therapy was attained in 16 (20.8%) of these patients.2
The data obtained from this single center would indicate that
single-dose stereotactic surgery is not a highly effective mode
of therapy if the goal is normalization of hyperprolactinemia.
2 Authors report a “cure” rate of 52%, which appears to include
patients treated with medical therapy following gamma knife
radiotherapy.
TABLE 5. Efficacy of single dose stereotactic radiotherapy on prolactinomas
Study Ref. Device Associatedtherapy
No. of
patients
No.
cured
Median or
mean follow-up
(months)
Margin dose
(Gy)
Levy et al. 140 Proton beam TSS (6/20) 20 12 12 NR-50–150
Gy in 4 fractions
Ganz et al. 131 GK TSS (2/3) 3 0 18 13.7
Lim et al. 141 GK TSS, DA(9) 18 10 26 25
Martinez et al. 142 GK TSS (1/5) 5 1 36 33
Mitsumori et al. 127 LINAC TSS 4 0 47 15
Morange-Ramos et al. 144 GK TSS 4 0 20 28
Yoon et al. 149 LINAC NR 13b 11 12 17
Hayashi et al. 132 GK NR 13 2 16 24
Inoue et al. 133 GK NR 2 1 24 20
Kim MS et al. 135 GK TSS (1), ?DAa 13 3 12 22
Kim SH et al. 136 GK TSS (4), ?DAa 18 3 27 29
Laws and Vance 139 GK NR 13 1 6 18
Mokry et al. 143 GK BRC, TSS 21b 4 31 14
Izawa et al. 134 GK NR 15 3 28 22
Landolt and Lomax 138 GK DA(9), TSS 20 5 29 25
Pan et al. 146 GK None 77 16 33.2 31.5
Feigl et al. 130 GK TSS or TCS 18 NR 55 15
Pollock et al. 148 GK BRC (3/7) 7 2 20 20
Choi et al. 129 GK TSS, ?DAa 21 5 42.5 28.5
Muramatsu et al. 145 LINAC NR 1 0 30 15
Kuo et al., Petrovich et al. 137, 147 GK TSS, CRTc (3) 15 11 42 15
TSS, Transsphenoidal surgery; NR, not reported; GK, gamma-knife; DA, dopamine agonist; BRC, bromocriptine; TCS, transcranial surgery;
CRT, conventional radiotherapy.
a It is unclear whether dopamine agonist therapy was used concomitantly in any of these patients.
b Some patients in these cohorts had normal PRL levels prior to RT.
c Three patients also received conventional radiotherapy following  knife for tumor remaining near optic chiasm.
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A second notable study by Landolt and Lomax (138) re-
ported the outcomes of 20 patients who underwent gamma-
knife radiosurgery after unsuccessful transsphenoidal sur-
gery and/or “failed” medical therapy. Normoprolactinemia
was achieved in five patients, all of whom were able to
discontinue medical therapy. For 11 patients, PRL levels
normalized or declined by at least 20%, but only with con-
tinuation of medical therapy. These subjects were regarded
as “improved”, although clearly in the absence of a control
group, any improvement attributed to the effects of radio-
therapy cannot be distinguished from effects of medical ther-
apy. Furthermore, the clinical significance of a 20% decline
in hyperprolactinemia is uncertain, because it would not be
expected to alter dopamine agonist therapy continuation or
dosage under these circumstances. Treatment with radio-
surgery failed entirely in four patients. Therefore, a 25%
complete response rate was achieved for gamma-knife ra-
diotherapy in this series.
E. Selecting the mode of radiotherapy
The advantages and disadvantages of various modes of
radiotherapy are important considerations when referring a
patient with a prolactinoma to a radiotherapist. Although it
is true that a large single dose of radiation is more effective
in cell death than the same dose delivered in several smaller
fractions, large single doses of radiation are more toxic to
normal tissue than similar doses given in a fractionated man-
ner. In the early days of single-dose radiotherapy, high doses
for large pituitary adenomas near the optic apparatus re-
sulted in a high incidence of optic neuropathy (150). The risk
of damage is dose dependent, with a 78% risk of optic neu-
ropathy in patients receiving more than 15 Gy and a 27% risk
for those receiving 10–15 Gy to the optic apparatus (151, 152).
To achieve an acceptable fall-off gradient with single-session
therapy, current practice aims at limiting irradiation of the
optic apparatus to single doses of less than 8 Gy (103, 112, 113,
139). As a result, pituitary adenomas with significant supra-
sellar extension, or those with less than 5-mm clearance be-
tween the tumor margin and the optic apparatus are poor
candidates for single-dose radiotherapy (103, 112, 139). On
the other hand, tumors with cavernous sinus invasion can be
good candidates for single-dose radiotherapy, because the
cranial nerves in the cavernous sinus are relatively radio-
resistant (112, 153, 154). Fractionated radiotherapy is also
preferable to single-dose radiotherapy when the tumor vol-
ume is so large (3 cm) that an effective radiation dose
cannot be safely delivered in a single session (112, 113, 139).
It is estimated, based upon extrapolation from an integrated
logistical formula, that the maximum diameter of a spherical
tumor that is treatable with a risk of complications less than
3% is approximately 35 mm (155).
Prospective evaluations of the rate of PRL normalization
in head-to-head comparisons of fractionated vs. single-dose
radiotherapy for prolactinomas have not been published.
Even if such series were to exist, one would need to critically
analyze the comparability of the tumors in each group. For
conventional radiotherapy, there is no restriction as to the
size of the tumor or the proximity to the optic apparatus. As
noted above, prolactinomas treated with single-dose radio-
therapy will largely consist of intrasellar adenomas well
away from the optic apparatus. In contrast, prolactinomas
treated with fractionated radiotherapy consist of not only
intrasellar adenomas, but also large adenomas with supra-
sellar extension that may lie in close proximity to the optic
apparatus. Complete hormonal and tumor growth responses
are undoubtedly more difficult to achieve in this latter cat-
egory of tumors.
In addition to patient convenience, one of the proposed
advantages of single-dose radiotherapy over fractionated ra-
diotherapy is its shorter latency to hormonal and tumor size
responses. It appears likely that single-dose radiotherapy
lowers PRL levels more rapidly than conventional external
beam radiotherapy, although prospective comparative stud-
ies are not available to verify this claim. Six of the 21 series
listed in Table 5 reported the latency to normalization of PRL
levels for their patients with prolactinomas treated with sin-
gle-dose radiotherapy; these responses ranged from 1 to 2 yr
(129, 137, 139, 147–149). The latency to normalization of hy-
perprolactinemia for conventional external beam radiother-
apy is on the order of several years.
F. Complications
The most frequent long-term morbidity of conventional
radiotherapy is radiation-induced hypopituitarism, with a
cumulative actuarial risk of approximately 50% at 10–20 yr
(111, 156, 157). Hypopituitarism is likely secondary to hy-
pothalamic and pituitary damage, although the former is
considered of primary importance (158). Recently, it has been
discovered that the consequences of hypopituitarism may be
more significant than issues related to hormone replacement
dosing and monitoring. A recent large prospective study
from the United Kingdom showed that the standardized
mortality rate was higher in patients with hypopituitarism
that had been treated with radiotherapy compared with
those who had not received radiotherapy (159). A large pro-
portion of this excess was due to a significant increase in
cerebrovascular disease-associated deaths in the radiother-
apy group.
Additional complications that occur months to years after
radiotherapy of pituitary adenomas include cerebrovascular
accidents, optic nerve damage, neurological dysfunction,
and soft tissue reactions (157, 160–162). Conventional radio-
therapy is associated with an increased risk of secondary
radiation-induced intracranial malignancies, with a cumu-
lative risk of 2.0% at 10 yr and 2.4% risk at 20 yr (163–165).
The incidence of hypopituitarism after single-dose stereo-
tactic radiotherapy is difficult to establish at present. The
reported rates of hypopituitarism vary widely, ranging from
0–36%, after single-dose radiotherapy (132, 134, 136, 141–
143, 148). These analyses are confounded by factors such as
previous pituitary surgery in some individuals. A long-term
follow-up study with a mean follow-up of 17 yr determined
a relatively high cumulative incidence of hypopituitarism at
72% (108). Cranial neuropathies have been reported after
single-dose radiotherapy. A high incidence of optic neurop-
athies was reported in the early use of single-dose therapy
when higher doses were administered. With dose changes
and technical improvements, these adverse effects are less
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frequent. The risk of damage to the optic apparatus is ap-
proximately 1%. The severity of these cases ranges from
nonspecific visual loss to blindness (113, 148, 166). Cranial
neuropathies involving nerves that traverse the cavernous
sinus (III, IV, V, VI) are less common and often transient (113,
153, 166). Radiation necrosis of surrounding brain tissue
occurs in approximately 0.2–0.8% of cases (113, 160). As of
yet with limited follow-up, there have been no reported cases
of secondary intracranial malignancies who have undergone
single-dose radiotherapy.
G. Conclusions with regard to radiotherapy
Overall, radiotherapy has a very limited role in the treat-
ment of patients with prolactinomas. The very high rate of
efficacy of dopamine agonists (see Section V) along with the
high complication rates of radiotherapy render treatment
with this modality rarely necessary. The few patients who
now require radiotherapy are those who do not respond to
dopamine agonists and who cannot then be cured by sur-
gery. When a large tumor remains after surgery, then con-
ventional radiotherapy is the best modality. However, a
small residual tumor, especially when involving the cavern-
ous sinus, may be better treated with stereotactic
radiotherapy.
V. Medical Therapy
The compounds used in clinical practice to treat prolacti-
nomas are all dopamine receptor agonists. Among these,
bromocriptine, cabergoline, pergolide, and quinagolide are
the most commonly used. The dopamine agonists lisuride
and terguride are less frequently used, as is metergoline, a
serotonin antagonist.
A. Pharmacological profile
Bromocriptine, pergolide, and cabergoline are all ergot
derivatives. The only nonergot derivative that is used in
clinical practice is quinagolide. The chemical structures of the
most used compounds are shown in Fig. 1. The ergot-deriv-
ative dopamine agonists comprise a group of indole alka-
loids that are predominantly found in various species of the
ascomycete Claviceps (167). The ergot alkaloids can all be
considered derivatives of the tetracyclic ergoline skeleton
and can be divided into two main groups based on their
structural characteristics (167). The first group includes all
lysergic acid derivatives of the acid amide types, such as
amine alkaloids (ergonovine) and the structurally more com-
plex ergopeptines (ergotamine, ergocristine). The second
group includes the so-called “clavine alkaloid” derivatives
that contain either a methyl or a hydroxymethyl group at
position 8 (167). The ergot alkaloids and their derivatives
have a wide spectrum of pharmacological actions that in-
clude central, neurohumoral, and peripheral effects, medi-
ated by norepinephrine, serotonin, and dopamine receptors.
The diversity of biological properties of ergot derivatives is
likely due to diverse mechanisms of action at the cellular and
molecular levels (167). Because ergot derivatives interact
with different receptor sites, it is not surprising that the drugs
developed (as well as the natural alkaloids) display a number
of side effects (167). The clinical application of ergot deriv-
atives in the treatment of other clinical conditions, such as
postpartum hemorrhage, migraine, and other vascular head-
aches, orthostatic hypotension, and Parkinson’s disease will
not be discussed here.
The octahydrobenzyl(g)-quinolines are a group of noner-
got oral medications that also function as dopamine agonists
with specific D2 receptor activity (168–170). Quinagolide and
SDZ 205–503 are slightly less active than their ergoline coun-
terparts, CPQ 201–403 and pergolide, in inhibiting basal PRL
secretion in rats (171, 172). Quinagolide is the most active
octahydrobenzyl(g)-quinoline and is about 35 times more
potent than bromocriptine. The octahydrobenzo(g)-quino-
lines bind more specifically to dopamine receptors than the
ergot derivatives bromocriptine, CQP 201–403, and pergol-
ide (167–174).
B. Mechanisms of action
In contrast to the other pituitary hormones, PRL secretion
is mainly regulated by the inhibitory tone exerted by dopa-
mine with minor additional inhibitory activity played by
-aminobutyric acid and cholinergic pathways (175). TSH-
releasing hormone, serotonin, estrogens, endogenous opi-
ates, and vasoactive intestinal polypeptide stimulate PRL
secretion, but their role is clearly minor compared with that
of dopamine (175).
Classically, dopamine receptors have been divided into D1
receptors, which stimulate adenylyl cyclase activity, and D2
receptors, which inhibit this enzyme (176–178); three further
discrete receptor subtypes have been described (D3, D4, and
D5) with less activity on PRL secretion (177). Dopamine in-
hibition of PRL secretion is mediated by the D2 dopamine
receptors expressed by normal and tumorous lactotrophs
(176–178). D2 receptors belong to the family of G protein-
coupled receptors, characterized by a single polypeptide
chain containing seven hydrophobic transmembrane do-
mains: besides their effect on adenylyl cyclase, they are able
to inhibit inositol phosphate production (179) with an effect
that involves G proteins sensitive to pertussis toxin (176–
179). Additionally, dopamine inhibits arachidonic acid re-
lease from pituitary cells independently from the other trans-
FIG. 1. Biochemical structure of dopamine agonists. Bromocriptine,
pergolide, and cabergoline are all ergot derivatives. Quinagolide is a
nonergot derivative.
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duction mechanisms (180). Two isoforms generated by
alternative splicing of the D2 dopamine receptor have been
described (181). These two isoforms differ by a 29-amino acid
additive sequence located within the third intracytoplasmic
loop that interacts with G proteins: dopamine inhibition of
adenylyl cyclase activity is observed with both isoforms.
Stimulation of D2 receptors by dopamine reduces adenylyl
cyclase activity that consequently reduces intracellular
cAMP levels in normal as well as in tumoral lactotrophs
(182). The inhibition of cAMP levels is a key step in the
inhibition of PRL release by dopamine (183). It is likely that
all dopaminergic ergot derivatives share similar mechanisms
of action (175).
Dopamine agonists reduce the size of prolactinomas by
inducing a reduction in cell volume (via an early inhibition
of secretory mechanism, and a late inhibition of gene tran-
scription and PRL synthesis), as well as causing perivascular
fibrosis and partial cell necrosis (184). There may also be a
true antimitotic effect of these drugs. Histologically there is
a reduction in secretory activity and cell size, an increase in
immunoreactive PRL cellular content and inhibition of exo-
cytosis (185).
C. Therapeutic profile of dopamine receptor agonists
1. Bromocriptine. More than 25 yr ago, bromocriptine was
introduced into clinical practice as the first medical treatment
for prolactinomas (186–188). Bromocriptine-mesylate is a
semisynthetic ergot derivative that has D2 receptor agonist
and D1 antagonist properties. It has a relatively short elim-
ination half-life, so that it is usually taken two or three times
daily, although once daily may be effective in some patients.
Generally, the therapeutic doses are in the range of 2.5–15
mg/d, and most patients are successfully treated with 7.5 mg
or less. However, doses as high as 20–30 mg/d may be
necessary for patients who demonstrate resistance. For mi-
croprolactinomas bromocriptine is successful in 80 to 90% of
patients in normalizing serum PRL levels, restoring gonadal
function, and shrinking tumor mass (175). For macropro-
lactinomas, normalization of serum PRL levels and tumor
mass shrinkage occur in about 70% of patients treated with
bromocriptine even when given at low doses; visual field
defects improve in the majority of patients (175). In most
patients, headache and visual field defects improve dramat-
ically within days after the first administration of bromocrip-
tine, with gonadal and sexual function improving even be-
fore complete normalization of serum PRL levels. Although
prolactinomas usually remain sensitive to bromocriptine,
this drug usually does not “cure” these pituitary adenomas,
and the withdrawal of therapy often results in recurrent
hyperprolactinemia; tumor regrowth may occur later, with
the consequent risk for compromised vision (see SectionVIII).
Prolonged bromocriptine treatment has been associated with
increased fibrosis of prolactinomas (189) and with increasing
tumor consistency. PRL normalization with bromocriptine is
also associated with an increase in bone density both in
women (190) and in men (191) and with improvement of
semen quality in men (192). Other formulations of bro-
mocriptine, long-acting and the long-acting repeatable forms
for im injections, an intranasal powder, and an intravaginal
tablet, were developed to overcome side effects such as nau-
sea, vomiting, postural hypotension, and headache (see Sec-
tion VI). These reactions were considered to be due to the
rapid absorption of bromocriptine, which is administered
two or three times a day, thus causing high blood levels.
However, despite promising data (190–195), none of these
formulations were ever introduced in the pharmaceutical
market for hyperprolactinemia. Bromocriptine (as a first-
generation dopamine receptor agonist) has been largely su-
perseded by more potent compounds with longer lasting
effects and improved side effect profiles. Nevertheless, bro-
mocriptine is still widely used to treat prolactinomas, pri-
marily in young women desiring pregnancy (see Section IX).
2. Cabergoline. Cabergoline is a D2 selective agonist widely
used to treat prolactinomas. It strongly suppresses PRL se-
cretion both in vivo and in vitro and preliminary studies
showed a significant PRL inhibition within 12 h after treat-
ment with cabergoline and bromocriptine in cultured pitu-
itary cells from estradiol-induced rat pituitary tumors (196,
197). Inhibition of de novo PRL synthesis was more pro-
nounced with cabergoline than bromocriptine treatment
(196). The continued oral administration of cabergoline sig-
nificantly reduced both PRL levels and the weight of the
pituitary during 15–60 d of treatment as compared with
bromocriptine (197). One single dose of cabergoline (0.2–0.6
mg) in healthy male volunteers induced a dose-dependent
PRL inhibition (198). In healthy men, single doses of 0.5, 1,
and 1.5 mg of cabergoline completely suppressed PRL levels
(1 g/liter) (199). In healthy women with regular menses,
cabergoline at doses of 0.4–0.6 mg induced a 43–76% PRL
suppression; PRL levels returned to baseline within 24 h after
the low 0.4-mg dose but remained suppressed until 5 d after
the administration of 0.6 mg (200).
The beneficial effects of cabergoline in resolving hyperp-
rolactinemia are widely known (201) (Table 6). Significant
decreases in serum PRL levels occur in as many as 95% of
hyperprolactinemic women during chronic cabergoline
treatment at a dose of 1 mg twice weekly (202). In a multi-
center, randomized, 24-wk trial conducted in 459 hyperpro-
lactinemic women (203), cabergoline induced normal PRL
levels in 83% compared with 59% with bromocriptine; ovu-
latory cycles or pregnancies were recorded in 72% vs. 52%,
and side effects were less frequent, less severe, and shorter
lived. In a retrospective study of 455 patients (204), caber-
goline treatment normalized PRL levels in 86% of 425 pa-
tients with available follow-up (92% of 244 patients with
idiopathic hyperprolactinemia or microprolactinoma, and
77% of 181 patients with macroprolactinoma); 13% had side
effects but only 4% discontinued cabergoline therapy be-
cause of side effects (204). Generally, the median dose of
cabergoline at the start of therapy was 1 mg/wk in patients
with macroprolactinomas and 0.5 mg/wk in those with id-
iopathic hyperprolactinemia or microprolactinomas (0.5
mg/wk) (201). A remarkable tumor-shrinking effect of caber-
goline has been observed in patients with macroprolactino-
mas (205): 12–24 months of treatment with cabergoline in-
duced a greater than 20% decrease of baseline tumor size in
more than 80% of cases, with complete disappearance of
tumor mass in 26–36% of cases. Moreover, Colao et al. (206)
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showed that cabergoline treatment induced further tumor
shrinkage in 60% of patients previously treated with other
dopamine-agonists compared with 82.3% of previously un-
treated patients (Fig. 2A). Cabergoline treatment is also ef-
fective and safe in patients with prolactinomas with onset in
childhood or adolescence (see Section X). The superiority of
cabergoline over bromocriptine was supported by a com-
parative retrospective study by Di Sarno et al. (207). Based on
these data, cabergoline treatment is clearly indicated as the
primary approach to macroprolactinomas. Lastly, cabergo-
line seems to induce fewer side effects than other dopamine
agonists (see Section VI). At present, cabergoline is certainly
the most effective compound to treatment prolactinomas,
with very good patient compliance with long-term treatment
regimens.
3. Pergolide. Pergolide is a synthetic ergoline derivative with
long-acting D2 and D1 agonist properties. This dopamine
agonist is approximately 100 times more potent than bro-
mocriptine and suppresses PRL secretion for up to 24 h after
a single dose (208–211), allowing effective control of hyper-
prolactinemia with once daily dosing. Pergolide is approved
in the United States only for the therapy of Parkinson’s
disease, where it has been used at doses more than 10 times
those used for PRL-secreting tumors (212). Pergolide has
advantages over bromocriptine in that it only requires once-
a-day dosing and is approximately one fifth of the cost. In
short-term studies, pergolide has been shown to effectively
lower PRL levels. In an open-label, randomized, controlled,
multicenter study, Lamberts and Quik (213) reported that
bromocriptine and pergolide were equally effective in low-
ering serum PRL levels and in inducing tumor shrinkage; a
high incidence of adverse events, such as nausea, dizziness,
vomiting, asthenia, headache, and decrease in blood pres-
sure, was reported with both drugs. Data concerning the
reduction of macroprolactinoma size by pergolide are lim-
ited (214–217). In the series of 22 patients with macropro-
lactinomas treated with pergolide reported by Freda et al.
(218), PRL levels normalized in 15 patients and approached
normal in two others. Prior studies of pergolide therapy of
both micro- and macroprolactinomas have shown high rates
of PRL normalization; PRL levels were normalized in 37 of
41 (218), 17 of 18 (219), and 16 of 25 (208) subjects treated for
periods from 6–24 months. The ability of pergolide and bro-
mocriptine to lower PRL also seems to be similar (208, 213,
220), but some patients who have not responded well to
bromocriptine have been reported to achieve better suppres-
sion of hyperprolactinemia with pergolide (221). In a recent
study enrolling 22 de novopatients with macroprolactinomas,
Orrego et al. (222) reported that after a mean of 12 months of
treatment with pergolide at a dose ranging from 0.05–0.5
mg/d, a mean PRL suppression of 88% was obtained, with
PRL levels being normalized in 15 patients and decreased to
25–40 ng/ml in another three. Shrinkage of tumor volume by
at least 75% of baseline was achieved in 10 patients (45.4%),
and shrinkage by at least 25% was achieved in 19 patients
(86.4%).
4. Quinagolide. Quinagolide is an octahydrobenzyl(g)-quin-
oline nonergot oral dopamine agonist with specific D2 re-
ceptor activity. Several studies demonstrated that once-daily
quinagolide treatment in women with hyperprolactinemia
reduced PRL levels and tumor size and relieved gonadal
dysfunction, thereby restoring fertility (223–230). In analogy
with the results of cabergoline, treatment with quinagolide
effectively reduced PRL levels, with normalization of sperm
parameters within 3 months in 13 of 14 men (231). In addi-
tion, tumor mass was reduced by at least 30% in eight of 13
men with macroprolactinomas (231). In a prospective, mul-
ticenter trial conducted in 26 patients with macroprolacti-
nomas who received once-daily quinagolide for 24 wk, tu-
mor size decreased in 21 patients, regular menses were
restored in 11 of 15 premenopausal women, and sexual func-
tion improved in five of seven males (229). From this study,
it appears that quinagolide is at least as effective as bro-
mocriptine. In fact, 81% of patients achieved normal PRL
TABLE 6. Overview of efficacy of cabergoline treatment in patients with hyperprolactinemic disorders.
Author Year Ref. Totalpatients Micro Macro
% PRL
normalization
% Tumor
reduction
% Side
effects
Prospective study
Ciccarelli 1989 599 30 27 3 81 71 48
Ferraria 1989 600 46 38 8 85 83 15
Ferrari 1992 347 127 108 19 90 79 23
Webster 1993 202 162 161 1 92 40
Webstera 1994 203 223 223 0 83 68
Biller 1996 353 15 0 15 73 73 0
Ciccarelli 1997 392 48 26 9 91 70 4
Colao 1997 323 27 8 19 85 48 22
Colao 1997 205 23 0 23 83 61 4
Muratori 1997 348 26 26 0 96 68 24
Cannavò 1999 349 37 26 11 92 100 8
Colao 2000 206 110 0 110 89 55 4.6
Di Sarno 2001 207 116 60 56 86 79 3.3
Colaob 2003 98 272 155 117 92 74c
Retrospective study
Ferrari 1997 354 65 0 65 61 66 25
Verhelst 1999 204 455 249 181 86 67 13
a Indicates series that include data from double-blind studies. All other studies were open-label.
b This series also contains data derived from an extension of the published study.
c Tumor reduction in this study was defined as 50%.
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levels after 24 wk of quinagolide treatment compared with
70% of bromocriptine-treated patients. However, there was
no significant difference between the treatment groups with
respect to the PRL levels at the end of the study. Both drugs
were able to restore menses and fertility and reduce the
incidence of galactorrhea in similar proportions of patients
(229). Side effects, however, limited the continuation of bro-
mocriptine but not of quinagolide treatment in another com-
parative study (226).
In a randomized, cross-over study, 20 patients with hy-
perprolactinemia received once-daily quinagolide or twice-
weekly cabergoline for 12 wk, with the two treatment phases
separated by a washout period of 12 wk with placebo (232).
A higher percentage of patients achieved normal PRL levels
with cabergoline compared with quinagolide (90 vs. 75%;P
0.05), but clinical efficacy, such as amenorrhea, oligomenor-
rhea, galactorrhea, and impotence, was similar as was the
occurrence of side effects (232). In another study, Di Sarno et
al. (224) compared the outcome of quinagolide and caber-
goline in a sequential treatment administered to 39 patients.
Treatment with quinagolide for 12 months was followed by
a 12-month washout period, and then cabergoline treatment
was given for a further 12-month period. The 12-month with-
drawal of dopamine agonist therapy was introduced in this
protocol to evaluate the recurrence of hyperprolactinemia.
After treatment with quinagolide for the first 12 months, PRL
levels normalized in 100% of patients with microprolactino-
mas and in 88% of patients with macroprolactinomas; tumor
volume was reduced by more than 80% in 22% of patients
with microprolactinomas and 25% of patients with macro-
prolactinomas. At the end of the washout period, PRL levels
increased in all patients, but were significantly lower than the
PRL levels measured at baseline before initiation of quinagol-
ide therapy. After 12 months of cabergoline treatment, PRL
levels normalized in 96% of patients with microprolactino-
mas and 88% with macroprolactinomas; tumor volume re-
ductions of more than 80% were noted in 30 and 31% of
patients with micro- and macroprolactinomas, respectively.
After 12 months of withdrawal from cabergoline treatment,
recurrence of hyperprolactinemia was observed in all pa-
tients with macroprolactinomas and 19 of the 23 patients
with microprolactinomas.
Giusti et al. (233) compared once-daily quinagolide (0.075
mg) with twice-weekly cabergoline (0.5 mg) in 12 patients
enrolled in a randomized cross-over study where treatment
with the second dopamine agonist was initiated after the
recurrence of hyperprolactinemia. Nine patients completed
both treatment cycles; the clinical effects were similar with
the two drugs and, interestingly, only one patient remained
resistant to both dopamine agonists. Quinagolide is currently
available in several European countries and in Canada but is
not available in the United States.
5. Other dopamine agonist compounds. Lisuride hydrogen
maleate is another synthetic ergot derivative, with PRL-
inhibitory activity in experimental models of hyperpro-
lactinemia (234). Liuzzi et al. (235) showed a potent inhi-
bition of PRL but not GH with 0.2 mg of lisuride in 12
patients with acromegaly. At a dose of 0.3– 0.6 mg/d for
7 d, lisuride effectively inhibited lactation and also sup-
pressed the serum PRL levels in 53 women with no un-
toward side effects (236). In another study enrolling pa-
tients with macroprolactinomas, Liuzzi et al. (186) showed
that lisuride and bromocriptine had similar tumor shrink-
ing effects, but withdrawal from treatment induced re-
currence of hyperprolactinemia in all cases.
Terguride, an analog of lisuride, binds to D2 receptors.
In a cohort of 20 patients with hyperprolactinemia, Dal-
labonzana et al. (237) showed that terguride, given for at
least 6 months in divided doses ranging from 0.25–1.50
mg/d, normalized PRL levels in 55% and induced tumor
shrinkage in three of five patients with a macroprolacti-
noma and in one of three patients with a microprolacti-
noma. Neither lisuride nor terguride is currently used in
the treatment of prolactinomas.
D. Serotonin receptor antagonists
Metergoline is a nonselective antagonist for 5-hydroxy-
tryptamine-1B and 5-hydroxytryptamine-1D receptors that
FIG. 2. Tumor shrinkage with cabergoline. A, Cabergoline induced
further tumor shrinkage in 60% of patients previously treated with
other dopamine-agonists, compared with 82.3% of previously un-
treated patients. F, De novo patients; E, patients intolerant to bro-
mocriptine; f, patients resistant to bromocriptine; , patients re-
sponsive to a previous treatment course of bromocriptine and treated
with cabergoline. Data are derived from Ref. 206. B, Comparison of
tumor reduction responses in micro- and macroprolactinoma with
bromocriptine or cabergoline. Data are derived from Ref. 207.
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has been used to treat hyperprolactinemia in the past. In a
group of lactating women, metergoline treatment induced
significantly higher responses of PRL to metoclopramide as
compared with those treated with either bromocriptine or
lisuride (238). Metergoline 8 mg/d given to 69 women within
24 h after delivery and continued for 5 d was able to prevent
lactation (239). Similar results were reported by Crosignani
et al. (240). In another study by the same group (241), 20
patients with hyperprolactinemic amenorrhea-galactorrhea
were treated with one or more of the following serotonin
antagonists: metergoline, methysergide, and cyprohepta-
dine. Among the 11 patients without evidence of pituitary
tumor, resumption of menses was observed in five, two of
whom had ovulatory cycles; one patient became pregnant;
ovulation occurred only during treatment with metergoline.
In the group of nine patients with enlarged sellae, three
experienced isolated episodes of bleeding, whereas two had
three and four menses each, respectively; all cycles were
anovulatory. In another study, metergoline, in a dosage of 4
to 24 mg/d, was administered for 1 to 8 months to 42 patients
with hyperprolactinemic amenorrhea. Metergoline treat-
ment restored menses in 37 patients; 28 patients ovulated,
and eight of them became pregnant (242). Although these
studies reported an efficacy of metergoline in normalizing
gonadal function and in restoring fertility in women, no data
are available in patients with macroprolactinomas or in men
with hyperprolactinemia. Metergoline is seldom, if ever,
used today in the treatment of prolactinomas.
E. Conclusions with regard to medical therapy
By far, the greatest experience in treating patients with
prolactinomas has been with bromocriptine and cabergoline.
In head-to-head randomized, prospective comparison stud-
ies (202), retrospective analyses (207), and general clinical
experience, cabergoline has been shown to be more effective
in lowering PRL levels to normal, reducing tumor size, and
having less adverse effects. As noted below, patients are less
likely to be resistant to the therapeutic effects of cabergoline;
furthermore, most patients found to be resistant to bro-
mocriptine subsequently respond to cabergoline. Finally,
treatment with cabergoline affords a greater chance of ob-
taining permanent remission and successful withdrawal of
medication, compared with treatment with bromocriptine
(see SectionVIII.C). Thus, in general, cabergoline is preferable
to bromocriptine as an initial therapeutic agent.
There is much less experience with pergolide and
quinagolide in the primary treatment of patients with pro-
lactinomas. However, these drugs appear to have similar
efficacy and adverse event profiles compared with bro-
mocriptine (see Section VI.C). When used in very high doses,
pergolide appears to have an increased association with or-
gan fibrosis, including cardiac valve fibrosis. Therefore, per-
golide should be avoided if high doses are needed. Depend-
ing upon pricing in some countries, pergolide may be less
expensive than other dopamine agonists, and this may factor
into its use. Pergolide has not been approved by the U.S. Food
and Drug Administration (FDA) for use in patients with
prolactinomas, and quinagolide is not approved for use in
the United States.
The single exception to a preference for cabergoline may
be for treatment of women who wish to become pregnant. As
discussed in Section VI.C , the safety database for bromocrip-
tine is far larger than that for cabergoline for fetal outcomes.
Although there are no particular worrisome aspects of this
smaller database for cabergoline, some clinicians and pa-
tients feel more comfortable using bromocriptine when fer-
tility is the desired outcome. On the other hand, the small
safety databases for pergolide and quinagolide are worri-
some, and we specifically recommend avoiding their use
when fertility is the desired outcome.
VI. Safety of Dopamine Agonists
A. Bromocriptine
The adverse effects of bromocriptine may be grouped into
three categories: gastrointestinal, cardiovascular, and neu-
rological (243). Symptoms tend to occur after the initial dose
and with dosage increases, but can be minimized by intro-
ducing the drug at a low dosage (0.625 or 1.25 mg/d) at
bedtime, by taking it with food, and by very gradual dose
escalation (175). Sometimes, tolerance develops to the ad-
verse effects, but occasionally, therapy withdrawal or dose
reduction followed by a more gradual reintroduction is re-
quired. Up to 12% of patients are unable to tolerate thera-
peutic doses of bromocriptine (244). The most common gas-
trointestinal effects are nausea (30%) and vomiting (20%)
(175, 243). Nausea tends to be more persistent. Constipation
is also frequent, with an incidence of up to 10%. Other re-
ported gastrointestinal effects include dry mouth, dyspepsia,
and symptoms suggestive of reflux esophagitis (175, 243). In
approximately 25% of patients, postural hypotension devel-
ops when initiating therapy and can result in dizziness and
even syncope (244). The syncope is rare, although it may be
observed even after a small initial dose (1.25–2.5 mg/d) at the
start of treatment. These symptoms can often be avoided by
taking the drug at bedtime or while recumbent, but tolerance
usually develops rapidly making this precaution unneces-
sary after the first few days. Up to 30% of patients receiving
high doses of bromocriptine (30 to 75 mg/d) experience a
syndrome of painless digital vasospasm causing blanching of
the extremities in response to cold (245, 246). However, this
reaction is rare at the low doses used to control PRL hyper-
secretion. Other less frequent side effects include leg cramps,
flushing, and nasal congestion (31, 247).
The most frequent neurological adverse effects include
headache and drowsiness. Psychiatric adverse effects are
infrequent at the bromocriptine doses required to control
PRL hypersecretion; however, low doses have been associ-
ated with mania in postpartum patients (243, 244, 248). Signs
and symptoms of psychosis or exacerbation of preexisting
psychosis have been associated with the use of bromocriptine
(249–251). Turner et al. (251) observed de novo psychotic
reactions in eight of 600 patients treated with bromocriptine
or lisuride, another dopamine agonist. The symptoms, which
included auditory hallucinations, delusional ideas, and
mood alterations, entirely remitted when the drug was re-
duced in dosage or discontinued (252). In a short-term trial
in which bromocriptine was given to 16 individuals with
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psychiatric disorders who were previously stabilized on neu-
roleptic agents, exacerbation of psychoses was not observed
(252). Although these data are reassuring, this study in-
cluded a small number of subjects with a limited exposure
to bromocriptine (10 wk). Thus, the safety of dopamine ago-
nists in this population remains to be established. Other
symptoms, usually associated with higher doses of bro-
mocriptine, include anxiety, depression, confusion, auditory
hallucinations, hyperactivity, disinhibition, insomnia, day-
time somnolence, and paranoia (244, 251, 253). Moreover,
dyskinesias similar to those observed with levodopa are
well-recognized effects of high-dosage treatment (244).
Other reported adverse effects include paraesthesia, night-
mare, blurred vision, diplopia (at high doses) and reversible
ototoxicity (in patients with chronic hepatic disease) (243,
244).
CSF rhinorrhea has been reported during treatment of
adults with bromocriptine, not only postsurgically, but also
in the absence of prior radiotherapy or surgical intervention
due to tumor shrinkage, when the tumor previously served
as a “cork” for the tumor-induced defect in the skull base
(254–259).
Individual case reports of postpartum women and other
adults treated with bromocriptine have suggested a causal
association between the use of bromocriptine and hyperten-
sion, thromboembolic events, severe leukopenia, hyponatre-
mia, and edema (260–264). However, conclusive evidence
that these events were drug-induced is lacking. In the United
States, the FDA has determined that bromocriptine should
not be used to treat postpartum lactation.
Rarely, in patients with Parkinson’s disease treated with
very high doses of bromocriptine, pulmonary infiltrates, fi-
brosis, pleural effusions, pleural thickening, and retroperi-
toneal fibrosis have been described (244); however, these
adverse effects appear to be dose-dependent and are unlikely
to occur at the low doses used for treatment of prolactinomas.
In a small group of patients at low doses of bromocriptine
(5–10 mg/d), transient asymptomatic increases in serum al-
kaline phosphatase and/or transaminases have been re-
ported (243, 244). Hyponatremia has been associated with the
use of bromocriptine in patients with cirrhosis and hepatic
encephalopathy (264).
B. Cabergoline
Side effects associated with the use of cabergoline are
similar to those reported for the other dopamine agonists, but
are generally less frequent, less severe, and of shorter du-
ration (31). Some effects subside with dose reduction or con-
tinued use in many patients (203). The long half-life of caber-
goline, which results in a relatively flat plasma drug
concentration, may be advantageous with respect to the in-
duction of side effects (265). The most common adverse event
is nausea or vomiting (35%), followed by headache (30%),
and dizziness or vertigo (25%) (244, 265). Diarrhea, drows-
iness, somnolence, paresthesias, and dyspnea are less com-
monly reported. Withdrawal of cabergoline treatment due to
side effects is reported in less than 3% of patients (244, 265).
Hypotension has been reported in approximately 50% of
women with hyperprolactinemia during cabergoline or bro-
mocriptine treatment with a median decrease in blood pres-
sure of 10 mm Hg (203). Generally, hypotension is asymp-
tomatic, because only one of 136 patients treated with
cabergoline for the inhibition of lactation (266) and three of
254 patients treated with cabergoline for hyperprolactinemia
(203) developed symptomatic hypotension. Side effects such
as thromboembolic events (265) or psychosis have not been
reported in patients with pituitary adenomas treated with
cabergoline. Pleuropulmonary inflammatory-fibrotic syn-
drome has been described in a few patients (267–269). Con-
strictive pericarditis was diagnosed in a patient with Par-
kinson’s disease receiving cabergoline therapy at the dose of
10 mg/d (270).
Recently, a number of case reports have been published
describing the occurrence of valvular insufficiency in pa-
tients who have been treated with high doses of cabergoline
(4 mg total daily dose) or pergolide (see Section VI.C) for
Parkinson’s disease. Both multivalvular (271) and single mi-
tral valve (272) heart disease have been described. In these
cases, the echocardiographic and/or microscopic features
resembled those found in valvular disorders associated with
ergot alkaloid agents and appetite suppressants (273, 274). In
one case of cabergoline-associated valvular disease, cardiac
symptoms improved with discontinuation of the drug (271);
mitral valve replacement was required in the second (272).
Although causality has not been proven, the similarity of the
echocardiographic findings, time course, and partial reversal
of symptoms in these cases suggests that the use of the
dopamine agonists in high doses may have been responsible
for these adverse cardiac effects. Therefore, extreme caution
should be exercised in titrating patients to high doses of
cabergoline or pergolide, and patients treated with higher
doses should be monitored for this adverse effect when the
drug is prescribed.
C. Pergolide
In general, the nature and incidence of most side effects
reported with pergolide are similar to those of bromocriptine
(208, 213, 275). Nausea, vomiting, dizziness, headache, and
postural hypotension are the most commonly reported ef-
fects. In one study, however, flushing, fever, and flu-like
symptoms were reported more commonly in adults treated
with pergolide than in those treated with bromocriptine
(213). As with the other dopamine agonists, daytime som-
nolence is commonly reported at very high doses (276). Chil-
dren with Tourette syndrome treated with pergolide in doses
of 150–450 g daily for tic reduction experience side effects
that are similar in nature and frequency to placebo (277).
Mild insomnia and mild rashes were the only side effects
observed more commonly in pergolide-treated children
compared with placebo. As discussed above, cases of per-
golide-associated valvular heart disease have been reported
in adults with Parkinson disease treated with doses much
higher than those used for the treatment of hyperprolactine-
mia (219, 278–280). An FDA survey of reported cases of
pergolide-associated valvular heart disease did not establish
causality, as a result of insufficient information and absence
of histological data (281). Nonetheless, the growing number
of reported cases of valvular heart disease at higher doses
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warrants routine clinical cardiac assessment of patients who
are treated with higher doses.
D. Quinagolide
Most adverse effects reported in adults taking quinagolide
are consistent with those reported for other dopamine ago-
nists, although they occur perhaps less frequently than with
bromocriptine (226, 233, 282–285). As with bromocriptine,
psychotic symptoms have been observed rarely, including
personality or behavioral changes, hypomania, and delu-
sions (286, 287). In one double-blind, randomized 6-month
study in 22 women with persistent hyperprolactinemia,
quinagolide was significantly better tolerated compared
with bromocriptine (226). No changes in blood biochemistry,
hematology, blood pressure or pulse rate were reported in
trials performed with quinagolide, confirming the favorable
safety profile (226, 283–285, 288, 289). Less frequent side
effects include anorexia, abdominal pain, constipation
and/or diarrhea, insomnia, flushing, edema, nasal conges-
tion, hypotension, and rare psychotic reactions (244).
VII. Dopamine Agonist Resistance
Although dopamine agonists have been proven to be suc-
cessful in normalizing PRL levels, alleviating symptoms of
hyperprolactinemia, and reducing tumor size, a subset of
individuals with prolactinomas do not respond satisfactorily
to these agents (290). In general, prolactinomas exhibit vary-
ing degrees of responsiveness to the class of dopamine ago-
nists, ranging from complete response at one end of the
spectrum to total resistance at the other. In addition, indi-
vidual prolactinomas may respond variably to selected do-
pamine agonists, such that tumors that respond poorly or
incompletely to one dopamine agonist may respond well to
another. The concept of dopamine agonist resistance must be
distinguished from that of dopamine agonist intolerance, in
which adverse effects of the medication prevent the achieve-
ment of an effective response.
A. Definition of dopamine agonist resistance
Varying definitions of dopamine agonist responsiveness
and resistance are used throughout the literature, including
failure to normalize PRL levels, failure to reduce PRL levels
sufficiently to achieve ovulation, or failure to enable a 50%
reduction of hyperprolactinemia (207, 282, 291, 292). In ad-
dition, there are no standard dose thresholds to which a
dopamine agonist should be titrated to assign an individual
to the status of “dopamine agonist resistant”. Obviously, the
percentage of patients deemed resistant to a particular drug
will depend upon this dose threshold.
The desired biological response in the treatment of hy-
perprolactinemia in women is the achievement of ovulation
regardless of the actual PRL level achieved. However, be-
cause this level varies on an individual basis, is difficult to
define, and is not provided in most papers, for the purposes
of the present analysis, dopamine agonist resistance with
respect to hormone levels will be defined as the failure to
achieve normoprolactinemia. Similarly, in an effort to
achieve uniformity, for the purposes of the present analysis,
dopamine agonist resistance with respect to tumor size will
be defined as the failure to achieve tumor size reduction of
50%.
B. Features and mechanisms
The molecular factors underlying the ability of some pro-
lactinomas to escape dopaminergic control are not fully un-
derstood. It is worth noting that the overall number of human
prolactinomas that have been characterized on a molecular
level, directly comparing resistant and responsive prolacti-
nomas, is limited. These studies are inherently challenging
for the following reasons. First, human-derived prolacti-
noma cell lines are relatively unavailable (293). Therefore, in
vitro studies of these tumors are largely restricted to the use
of primary (short-term) cultures. Second, as noted by their
insensitivity to inhibitory signals and histologically aggres-
sive nature, these particular tumors have acquired multiple
intrinsic molecular defects that result in autonomous capa-
bilities, such as escape from apoptosis and/or an unre-
strained replicative potential, which are likely to have a di-
verse molecular basis (294). The substantial genetic
heterogeneity among these tumors complicates our ability to
dissect out individual factors that are responsible for the
development of drug resistance.
The obvious candidate for a molecular alteration leading
to dopamine agonist resistance is the lactotroph dopamine
D2 receptor itself (Fig. 3). Thus far, mutations in the D2
receptor have not been identified in human prolactinomas,
although it should be noted that a limited number of these
tumors have been subject to such a molecular analysis (295).
Several studies have examined the expression and affinity of
D2 receptors in resistant prolactinomas, as well as proximal
downstream signaling effectors of the D2 receptor (296).
There is experimental evidence that some dopamine ag-
onist-resistant prolactinomas have a reduced density of D2
receptors (292, 297, 298). The initial studies documenting this
finding were reported by Pellegrini et al. (292), who com-
pared dopamine receptor density and affinity in primary cell
cultures of prolactinomas derived from bromocriptine-sen-
sitive (n  10) and resistant (n  8) patients. The density of
dopaminergic binding sites, as assessed by [3H]spiroperidol
(a selective D2 receptor antagonist) was reduced by 50% in
the group of resistant prolactinomas overall compared with
the group of bromocriptine-sensitive adenomas. The binding
affinity, nonetheless, was similar. On an individual basis, the
dopamine receptor density was highly variable, so that a
clear distinction in dopamine receptor expression between
sensitive and resistant tumors was not discernible. Five of the
resistant prolactinomas that actually grew during therapy
showed a dramatic reduction in D2 receptor sites, exhibiting
only 10% of the number of dopaminergic binding sites found
in normally responsive tumors. In the majority of tumors,
adenyl cyclase activity within the cells paralleled the changes
in D2 receptor number proportionately, demonstrating that
although reduced in number, the D2 receptors from the re-
sistant prolactinomas couple normally to adenyl cyclase.
However, for the tumors that grew during therapy, dopa-
mine paradoxically stimulated adenyl cyclase activity. For
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this subset of resistant tumors, the possibility of abnormal
coupling of the D2 receptor to second messengers (Gi2
proteins), in addition to an overall reduction in D2 receptor
expression, cannot be excluded. Unexpectedly, in this subset
of tumors, the bromocriptine-induced stimulation of adenyl
cyclase was not associated with a further increase in PRL
release. The significance of this finding remains uncertain,
although it raises speculation that the increase in adenyl
cyclase activity may have reflected preserved activation of
adenyl cyclase subtype 2, which is stimulated by D2 receptor
activation and lies upstream of mitogenic signaling path-
ways (299, 300).
Since this initial report documenting a reduction in D2
receptor expression among bromocriptine-resistant prolacti-
nomas, some (298, 301), but not all (302, 303), studies have
corroborated these findings. For example, Caccavelli et al.
(301) found a 4-fold lower level of D2 receptor mRNA and
5-fold lower number of D2 binding sites among bromocrip-
tine-resistant compared with bromocriptine-sensitive pro-
lactinomas, but Kovacs et al. (302), demonstrated preserva-
tion of both D2 receptor mRNA and protein expression in
their prolactinoma resistant to dopamine agonist therapy.
Thus, the absence of D2 receptor expression is not a universal
finding among prolactinomas resistant to dopamine agonist
therapy. It may, however, be associated with the progression
to a more dedifferentiated state (41).
A second area of investigation into the mechanism of do-
pamine agonist resistance has focused on differences in the
proportion of short (D2S) and long (D2L) dopamine receptor
variants and correlating this with the degree of dopamine
agonist responsiveness. As noted earlier, the D2 receptor
exists as two different isoforms generated by alternative
splicing: the long (D2L) and the short (D2S) isoforms, which
differ in the presence or absence of a stretch of 29 amino acids
within the third cytoplasmic loop. The two molecular forms
of the receptor display comparable binding characteristics,
but they are regulated differently (297, 304) and may couple
selectively to different G proteins (305, 306). The D2S receptor
may be more efficient than the D2L at coupling to adenyl
cyclase (307, 308). Using quantitative RT-PCR, both the short
and long isoforms were found in sensitive prolactinomas, in
equivalent proportions to that reported for normal pituitary
lactotrophs (301). By contrast, the proportion of mRNA cor-
responding to the D2S was lower in resistant compared with
responsive prolactinomas (D2S/D2L ratio  0.74 and 1.00,
respectively). The significance of this altered ratio is uncer-
tain, because the magnitude of the decrease in D2S receptor
expression is of limited amplitude, compared with a 4-fold
overall lower expression of the D2R. Consequently, alter-
ations in the ratio of the receptor variants may contribute to
(but are unlikely to solely determine) the spectrum of do-
pamine agonist responsiveness observed among prolactino-
mas (309).
A few studies have investigated alterations in G protein
FIG. 3. Schematic illustration of signaling pathways in pituitary lactotrophs. For simplicity, major pathways are illustrated, and the reader
is referred to recent reviews for more extensive detail (183, 520, 626). Alterations in several of these signaling pathways have been identified
in human prolactinomas (see Tables 14 and 15). Activation of the D2 receptor, and to a lesser extent the somatostatin receptor (SSTR), results
in the inhibition of PRL synthesis and secretion through a number of pathwaysmediated by severalG proteins. Gi2mediatesD2-induced adenyl
cyclase 5 inhibition and subsequent reduction in intracellular cAMP, probably the major pathway involved in the inhibition of PRL gene
transcription, as well as the inhibition of phospholipase C activity, which is necessary for activation of phosphoinositide pathways. D2 receptor
activation also stimulates MAPK, ERK1, and ERK2, thereby inhibiting cell proliferation. Estradiol (E2) stimulates PRL gene transcription (in
a classic mechanism) by binding to estrogen response element located in the PRL promoter. NGF receptor (NGFR) signaling stimulates
expression of D2 receptor. AC5, Adenyl cyclase type 5; AC2, adenyl cyclase type 2; FGF, fibroblast growth factor; PLC , phospholipase B; PP2B,
protein phosphatase 2B; RTK, receptor tyrosine kinase; EGFR, epidermal growth factor receptor; PRL-R, PRL receptor; BMP 4, bone mor-
phogenetic protein 4; CREB, cAMPelement binding protein; PKA, protein kinaseA; PKC, protein kinaseC; P13K, phosphatidylinositol 3-kinase;
AKT, protein kinase B; , -subunit of G protein; , -subunit of G protein; and , -subunit of G protein.
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subunits as contributing factors to bromocriptine resistance.
Two rat PRL-secreting pituitary tumor cell lines (7315a and
MtTTW15) that are resistant to dopamine agonists display a
reduction in Gi2 and Go content, compared with normal
rat pituitary (310, 311). A study of human bromocriptine-
resistant prolactinomas corroborated the finding of a reduc-
tion in Gi2 among resistant prolactinomas, although no
differences in Go or GsmRNA levels were observed (312).
The relative Gi2 expression correlated with the D2 receptor
expression, as well as the ability of bromocriptine to inhibit
PRL secretion in vitro. Therefore, a common regulatory ele-
ment involved in D2 receptor and Gi2 subunit expression
may contribute to dopamine agonist resistance in some
prolactinomas.
A third major area of investigation has focused on the role
of autocrine pathways of inhibitory growth signaling in the
development of dopamine agonist resistance in human pro-
lactinomas. Missale and Spano (313) have identified a nerve
growth factor (NGF)-mediated autocrine loop that controls
cell proliferation and differentiation in pituitary lactotrophs.
This autocrine loop is present in dopamine-sensitive pro-
lactinomas but lost in dopamine-resistant tumors. A thor-
ough analysis and comparison of the NGF system has re-
vealed that dopamine-sensitive prolactinomas secrete high
levels of NGF and express both p75NGFR and trkA receptors
for NGF (314). In contrast, dopamine-resistant prolactinomas
do not produce NGF and express the trkA but not the
p75NGFR receptor (314). Exposure of the dopamine-resistant
cells to exogenous NGF induces expression of NGF mRNA,
production and secretion of biologically active NGF, and the
expression of p75NGFR receptors, thus restoring the autocrine
loop. More impressively, treatment of the dopamine-resis-
tant cells with NGF promotes their differentiation, induces
expression of both the p75NGFR receptor and D2R, inhibits
proliferation, and abrogates the tumorigenic potential of
these cells in vivo (298, 315). Conversely, ablation of NGF
production in dopamine-responsive cells leads to transfor-
mation and D2R loss (314). Purportedly, the reestablishment
of the NGF-mediated autocrine loop induced a permanent
effect, because it was maintained in daughter cells even upon
withdrawal of exogenous NGF. The molecular mechanisms
underlying the “redifferentiating” effects of NGF are under
investigation but appear to involve two events. First, NGF
appears to regulate D2R expression by inducing p75
NGFR
receptor-mediated nuclear translocation and activation of
nuclear factor-B (316). Second, NGF promotes a conforma-
tional change in the tumor suppressor p53 that permits its
nuclear translocation and reconstitutes its DNA binding ac-
tivity (317).
To summarize, there is solid evidence that some dopamine
agonist-resistant prolactinomas are associated with a reduc-
tion in D2 receptor density but not an alteration in binding
affinity. Some dopamine agonist-resistant prolactinomas
may exhibit disruptions in the autocrine growth factor sig-
naling pathway mediated by NGF, which may contribute to
the progression of these tumors. Whether alterations in D2
receptor isoform ratios are altered, related to differences in
G protein specificity, or of major significance in mediating
dopamine agonist resistance remains to be determined. Fi-
nally, it should be emphasized that additional undiscovered
molecular alterations further downstream of the D2 receptor,
and/or alterations altogether unrelated to D2 receptor sig-
naling, may contribute or cause insensitivity to inhibitory
dopaminergic influence, especially in more dedifferentiated
tumors.
C. Unusual presentations
Under most circumstances, the normalization of PRL lev-
els achieved with a dopamine agonist is accompanied by
substantial tumor size reduction. However, unusual cases of
selective dopamine agonist resistance have been reported in
a few patients exhibiting discordant responses to the PRL-
lowering and tumor size-reducing effects of bromocriptine.
Because of the discordance of response seen in many pa-
tients, both the PRL response and the tumor size response
will be discussed separately, where appropriate, using the
definitions of dopamine agonist resistance outlined above,
i.e., failure to normalize PRL levels and failure to decrease
tumor size by at least 50%.
Rarely, patients who initially respond to dopamine agonist
therapy later become resistant (318–320). For example, Del-
grange et al. (321) reported an unusual case of a macroad-
enoma that responded well to bromocriptine for 5 yr, yet
later became resistant. The mechanism for this late loss of
responsiveness is not known. Rarely, a benign prolactinoma
will develop dopamine agonist resistance upon malignant
transformation (322), a phenomenon that should be inves-
tigated in patients who develop late resistance to dopamine
agonists (320). Noncompliance with medications can lead to
a clinical situation that mimics resistance, as a result of side
effects generated by discontinuing a drug, followed by re-
sumption of the full dose. Under these circumstances, drug
intolerance, rather than tumoral resistance, is responsible for
the unsatisfactory response.
D. Resistance to prolactin-lowering effects
On the basis of the efficacy data presented in Section IV
(Medical Therapy), it is possible to estimate the prevalence
of resistance to the specific dopamine agonists with respect
to the normalization of PRL. Overall, approximately 24, 13,
and 11% of patients demonstrate resistance to bromocriptine,
pergolide, and cabergoline, respectively. Resistance to
quinagolide is difficult to ascertain, because there are no
large published series in which quinagolide was given to
totally drug-naı¨ve patients, which would allow determina-
tion of the percentage of patients responding with a nor-
malization of PRL levels in the absence of any prior drug
therapy. Virtually all of the studies testing the efficacy of
quinagolide were conducted in patients who had previously
been treated with bromocriptine.
It is of clinical interest to know whether resistance to do-
pamine agonists represents a class effect. Most of the clinical
data regarding dopamine agonist resistance involve studies
investigating whether another dopamine agonist may be
effective in patients resistant to bromocriptine. Of all the
dopamine agonists, cabergoline has been shown to be most
effective in normalizing PRL levels in patients resistant to
bromocriptine. Approximately 80% of bromocriptine-resis-
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tant patients obtain a normalization of PRL on cabergoline
(204, 323). Colao et al. (323) showed that 85% of 20 patients
resistant to both bromocriptine and quinagolide responded
with a normalization of PRL levels, and 70% responded with
some change in tumor size. A subgroup analysis from a large
study of patients treated with cabergoline found that 70% of
58 patients in whom bromocriptine failed to normalize PRL
were controlled with cabergoline (204). These patients did
require higher doses of cabergoline (1.5 mg/wk) compared
with the overall cohort (0.5 mg/wk). Seven (12%) of the
patients previously found to be resistant to bromocriptine
were completely resistant to cabergoline (50% decrease in
PRL levels). It is not known for certain why cabergoline can
be effective in patients resistant to bromocriptine, but pos-
sible explanations include the higher affinity of cabergoline
for dopamine binding sites, its greater occupancy of the
receptor, and slower elimination from the pituitary (324).
Two large, prospective European randomized studies
compared bromocriptine to cabergoline with respect to drug
efficacy, thus allowing a comparison of the prevalence of
resistance to each drug within the same study. In the Euro-
pean Cabergoline Collaborative Study, PRL was normalized
in 48 of 74 (65%) women taking bromocriptine and in 66 of
72 (92%) women taking cabergoline (203). In a multicenter
study conducted in France, 27 of 58 (48%) women taking
bromocriptine and 56 of 60 (93%) women taking cabergoline
normalized their PRL levels (325). A third retrospective anal-
ysis by Di Sarno et al. (207) compared rates of drug resistance
between a group of patients who were taking bromocriptine
initially in the 1980s to another group of patients taking
cabergoline initially (in the same clinic) when it became avail-
able in the late 1980s. Of patients with microadenomas, 57%
of 44 patients taking bromocriptine and 90% of 60 patients
taking cabergoline normalized their PRL levels (207). Simi-
larly, of patients with macroadenomas, 46% of 28 patients
taking bromocriptine and 82% of 46 taking cabergoline nor-
malized their PRL levels (207).
Quinagolide (CV 205–502) has been shown to be effective
in improving hyperprolactinemia in some patients resistant
to bromocriptine, although the ability of quinagolide to nor-
malize hyperprolactinemia in these patients varies widely
among the studies (225, 282, 284, 326–329). There are spo-
radic reports of using pergolide in bromocriptine-resistant
patients that show only modest efficacy (221, 330).
E. Resistance to mass-reducing effects
There are no prospective, randomized series that have
compared one dopamine agonist to another with respect to
their abilities to decrease tumor size. Therefore, three series
have been selected that are comparable in many aspects with
respect to relative abilities of tumor size lowering (Table 7).
In these series, PRL levels could be lowered to normal in 66,
68, and 100% and tumor size decreased by at least 50% in 64,
86, and 96% of patients receiving bromocriptine (187), per-
golide (218), and cabergoline (206), respectively. However, it
should be noted that the times of final assessment of the
efficacy of these drugs were different; the effects of pergolide
and cabergoline were assessed at comparable times at 27 and
24 months, whereas the effects of bromocriptine were as-
sessed at 12 months. Because the process of tumor mass
reduction may continue after 1 yr, it is possible that the
efficacy of bromocriptine in reducing tumor size is under-
estimated by the figures presented in Table 7.
On the basis of the studies cited above for PRL level re-
duction and tumor size reduction, it is possible to make a
rough, overall comparison of the three evaluable dopamine
agonists. With respect to lack of normalization of PRL levels,
resistance can be expected in 25–50% of patients taking bro-
mocriptine, 10–30% taking pergolide, and 5–18% taking
cabergoline. With respect to failure to achieve at least a 50%
decrease in tumor size, resistance can be expected in about
one third of those taking bromocriptine, about 15% of those
taking pergolide, and 5–10% of those taking cabergoline.
F. Treatment approaches
The possible treatment approaches for patients with pro-
lactinomas that demonstrate dopamine agonist resistance
include: 1) trial of an alternative dopamine agonist; 2) esca-
lation of the dopamine agonist beyond conventional doses;
3) surgical tumor resection; 4) radiotherapy; and 5) experi-
mental treatments. As noted above, some patients who re-
spond do not respond to one dopamine agonist will respond
to another, and vice versa. Another approach is simply to
continue increasing the dose of the medication as long as a
continued response can be documented. About 80–90% of
patients who respond to dopamine agonists will do so rap-
idly and with low doses. However, about 5% of patients
respond with a step-wise reduction in PRL levels with each
increase in dose. Di Sarno et al. (207) found that incremental
increases in cabergoline doses led to step-wise reduction in
PRL levels in 18% of patients with macroadenomas and 10%
of those with microadenomas. Increasing the weekly dose of
cabergoline to 7 mg/wk permitted recovery of gonadal and
sexual function in 30% of those with macroadenomas and all
of those with microadenomas (207). A patient we recently
reported required up to 3 mg/d of cabergoline to reduce PRL
levels to less than 100 g/liter (331). In general, large doses
of cabergoline are very well tolerated, as demonstrated by
the many studies in which this drug has been used to treat
Parkinson’s disease (56–58). As long as adverse effects from
TABLE 7. Tumor size reduction with various dopamine agonists
Drug Bromocriptine Pergolide Cabergoline
Ref. 187 218 206
No. of patients 27 22 26
Baseline PRL (g/liter) 2260  539 2938  780 1013  278
Normalization of PRL (%) 66 68 100
% with 50% tumor shrinkage 64 86 96
Time of assessment (months) 12 27 24
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higher doses do not develop, dose escalations are reasonable,
with the awareness that doses of cabergoline greater than 2.0
mg/wk are beyond what is recommended in the package
insert. Thus, once a patient has been switched to the most
efficacious and well-tolerated drug (usually cabergoline), the
dose may be raised cautiously. However, as noted above,
cardiac valvular fibrosis may occur in patients taking large
doses, and patients should be monitored for this possibility.
Transsphenoidal surgery remains an option if the tumor is
potentially resectable and an experienced neurosurgeon is
available. Radiotherapy may be effective in controlling tu-
mor growth, although its efficacy in restoring PRL levels to
normal is limited. If fertility is a major concern, induction of
ovulation is possible in hyperprolactinemic patients even
without lowering PRL levels, using clomiphene citrate, go-
nadotropins, and pulsatile GnRH (332–334). A number of
experimental therapies in various phases of development are
available, as discussed in Section XII (Experimental Therapy),
although these methods should be reserved for situations in
which all other standard therapies have failed.
VIII. Dopamine Agonist Withdrawal
A. Overview
As already discussed in detail, the primary medical treat-
ment of prolactinomas with dopamine agonists is highly
effective in controlling the hyperprolactinemic syndrome,
i.e., recovery of gonadal function, control of tumor growth,
and recovery of neurological symptoms (15). The apprecia-
tion for medical therapy with dopamine agonist compounds
is based not only on excellent clinical results but also on the
evidence that surgery resulting in normal PRL levels has a
high risk of recurrence of hyperprolactinemia (85, 335, 336).
Previously, cure of a prolactinoma has been defined and
regarded as the complete removal of tumor through surgical
resection (31). In the past, withdrawal from medical therapy
has been generally reported to result in a greater incidence
of recurrent hyperprolactinemia compared with that ob-
served after surgery (Table 8). As a result, the principal
shortcoming of dopamine agonist treatment has been per-
ceived to be its supposed lifelong requirement. In fact, in the
first study reporting results of bromocriptine withdrawal,
Johnston et al. (337) showed that PRL levels remained sig-
nificantly lower than those before initiating therapy, but they
remained within the normal range in only two of 37 treated
patients. Several other studies have evaluated recurrence
after discontinuation of bromocriptine, all of which have
reported quite disappointing results, as detailed in the fol-
lowing sections. More recently, in an prospective, observa-
tional, analytical study conducted in 200 patients with hy-
perprolactinemia undergoing cabergoline withdrawal,
Colao et al. (98) reported a prevalence of persistent normo-
prolactinemia, independent of baseline tumor size, in more
than 60% of the patients, thus providing anticipation for
greater long-term successful withdrawal with this drug.
Overall, in that prospective study, over the time of follow-up
using MRI scans, complete disappearance occurred in 46 of
117 (39.3%) patients with macroadenomas and 63 of 194
(32.5%) patients with microadenomas. This section focuses
on the possibility of withdrawing dopamine agonist therapy
in patients with prolactinoma, first analyzing the results
reported in the literature, followed by a highlight of the
authors’ personal experience and perspective, ending with a
proposed protocol for withdrawal of treatment that may be
applied in clinical practice.
B. Bromocriptine withdrawal
After withdrawal of bromocriptine (Table 8), remission
rates have been reported from as low as 0 to 9% (337–340) to
as high as 20 to 44% (97, 125, 341–344). In the only study
restricted to patients with macroprolactinomas, van’t Verlaat
and Croughs (345) reported a remission rate in 8% of 12
TABLE 8. Literature review on dopamine agonist withdrawal
Author Ref.
No. of subjects
Drug Treatment duration(months)
Normal PRL
(%)
Follow-up duration
(months)Total Micro Macro NTH
Johnston et al. 337 37 19 BRC 12–72 5.4 0.5
Zarate et al. 344 16 0 BRC Mean 24 37.5 24
Moriondo et al. 341 36 36 0 0 BRC Mean 12 22 Up to 30
Johnston et al. 339 13 5 6 2 BRC Mean 44 7.7 1–12.5
Johnston et al. 339 2 1 1 0 PER 24 0 2
Maxson et al. 340 7 7 0 0 BRC 12 0 2
Wang et al. 125 24 15 4 5 BRC Mean 24 21 12–48
Winkelmann et al. 343 40 BRC 18.4 5–25
Rasmussen et al. 283 75 BRC Mean 24 44 6
van’t Verlaat et al. 345 12 0 12 0 BRC Median 60 8.3 12
Ferrari et al. 347 65 42 7 15 CAB Median 14 31.3 (yr 1) 3–24
66.7 (yr 2)
Muratori et al. 348 26 26 0 0 CAB 12 19 38–60
Cannavò et al. 349 37 26 11 0 CAB 24 13.5 12
Di Sarno et al. 224 39 23 16 0 CV 12 0 0.5–2
Di Sarno et al. 224 39 23 16 0 CAB 12 10.2 12
Passos et al. 342 131 BRC Mean 47 20.6 Mean 44
Colao et al. 98 200 CAB 24 24–60
Biswas et al. 97 22 22 0 0 BRC Median 36 50 12
Biswas et al. 97 67 67 0 0 CAB Median 36 31.3 12
BRC, Bromocriptine; CAB, cabergoline; NTH, nontumoral hyperprolactinemia; PER, pergolide; CV, quinagolide.
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patients after 12 months. Importantly, an increase of tumor
volume with clear-cut reexpansion has been found in less
than 10% of cases (188, 222, 346) after bromocriptine discon-
tinuation. Tumor regrowth appears to depend upon the du-
ration of previous treatment, although the cumulative data
to this point are too sparse to draw definitive conclusions (97,
98, 125, 337–345).
C. Cabergoline withdrawal
As noted above, cabergoline has been associated with sub-
stantial success with respect to tumor mass reduction in
macroadenomas. In light of its efficacy in this regard, it was
anticipated that cabergoline might achieve a greater likeli-
hood of remission of hyperprolactinemia (compared with
bromocriptine) after treatment withdrawal. Results of stud-
ies investigating withdrawal from cabergoline treatment re-
main limited. Persistent normoprolactinemia was found by
Ferrari et al. (347) in 31.2% of 32 patients; by Muratori et al.
(348) in 24% of 25 patients; by Cannavo` et al. (349) in one
patient with a macroprolactinoma (11%) and four with mi-
croprolactinomas (22%); and by Biswas et al. (97) in 31.3% of
67 patients (Table 8). In a sequential study aiming at com-
paring the efficacy of a 12-month course of treatment with
quinagolide and cabergoline in 39 patients (23 with micro-
prolactinoma and 16 with macroprolactinoma), Di Sarno et
al. (224) also found persistent normoprolactinemia in none of
the patients during the treatment with quinagolide and in
10.2% (17.4% of 23 microprolactinomas) treated with caber-
goline (Table 8). All the studies reporting the results of caber-
goline withdrawal, with the exception of the one by Biswas
et al. (97), were prospective. The limitations of the studies
above were both the small series of patients studied and the
lack of criteria for treatment withdrawal. Moreover, the
study by Di Sarno et al. (224) did not have the goal of in-
vestigating the effects of treatment withdrawal but was fo-
cused on the comparison of the efficacy between the two
drugs. Therefore, the outcome of cabergoline treatment and
withdrawal could be biased by the previous treatment with
quinagolide.
The more recent study by Colao et al. (98) reported a
Kaplan-Meier estimate of recurrence rate of hyperprolactine-
mia after 5 yr of cabergoline withdrawal of only 24% in
patients with nontumoral hyperprolactinemia, 32.6% in pa-
tients with microprolactinomas, and 43.3% in those with
macroprolactinomas. MRI evidence of tumor regrowth was
not found in any patient; only 10 women (22.2%) and seven
men (38.9%) with recurrent hyperprolactinemia redeveloped
gonadal dysfunction. In accord with previous studies, PRL
levels at recurrence were significantly lower than at diag-
nosis in all groups. The patients showing small remnant
tumors on MRI at treatment withdrawal, with either macro-
or microprolactinomas at their diagnosis, had a higher esti-
mated recurrence rate after 5 yr than those without evident
tumor (macroprolactinomas 77.5 vs. 32.6%, P  0.001; mi-
croprolactinomas 41.5 vs. 26.2%, P  0.02). Age, basal PRL
levels, nadir PRL levels (Fig. 4), percent PRL suppression,
nadir tumor diameter after cabergoline (Fig. 5), treatment
duration, and cabergoline dose were all higher before treat-
ment withdrawal in patients developing a recurrence of hy-
perprolactinemia compared with those achieving persistent
control (98). A Cox regression analysis (Fig. 6) indicated that
the nadir value of maximal tumor diameter during caber-
goline treatment was the best predictor of persistent hyper-
prolactinemia after withdrawal (2  12; P  0.001); the
hazard rate for each millimeter of maximal tumor diameter
measured on MRI before treatment withdrawal on recur-
rence of hyperprolactinemia was 19% (98). These results sup-
port the concept of periodic treatment withdrawal, especially
in the patients with no tumor visible on MRIs during treat-
ment. However, until longer follow-up data are available,
particularly in patients with macroadenomas for whom tu-
mor regrowth may compromise vision, patients should be
closely monitored for recurrent hyperprolactinemia and tu-
mor regrowth.
FIG. 5. Side-by-side demonstration of maximal tumor diameter
achieved during treatment with cabergoline in those patients who
developed recurrence of hyperprolactinemia (F) after treatment with-
drawal and those who sustained remission (E) after treatment with-
drawal. The nadir tumor diameter was larger before treatment with-
drawal in those patients who developed recurrence of
hyperprolactinemia. Data are derived from Ref. 98.
FIG. 4. Side-by-side demonstration of nadir PRL levels achieved dur-
ing treatment with cabergoline in those patients who developed re-
currence of hyperprolactinemia (F) after treatment withdrawal and
those who sustained remission (E) after treatment withdrawal. The
nadir PRL was higher before treatment withdrawal in those patients
who developed recurrence of hyperprolactinemia. Data are derived
from Ref. 98.
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D. Withdrawal of other dopamine agonists
The results of treatment withdrawal with other dopamine
agonists are limited. As shown in Table 8, the outcomes of
only two patients have been reported after pergolide with-
drawal (339) and of 39 patients after quinagolide withdrawal
(224); PRL levels did not remain normal in any of these cases
(224, 339). The latter study was not designed to address the
issue of quinagolide withdrawal, which was performed only
as a washout period before changing to cabergoline treat-
ment. Therefore, the paucity of the data does not permit
conclusive statements on treatment withdrawal with other
dopamine agonists.
E. Other conditions associated with remission of
hyperprolactinemia
Two other conditions, apart from previous surgery and/or
radiotherapy and bromocriptine or cabergoline withdrawal,
are known to facilitate the remission of hyperprolactinemia:
pregnancy (350, 351) and menopause (352). Among the 200
patients (156 women) we enrolled in the study of cabergoline
withdrawal (98), recurrence of hyperprolactinemia was not
found to be associated with gender (P  0.928) or with
menopause (27.5% in premenopausal and 36% in postmeno-
pausal women; P  0.5). In our study, we excluded the
patients undergoing treatment discontinuation for preg-
nancy. Nevertheless, remission of hyperprolactinemia has
also been described in untreated tumors during their natural
history. Spontaneous regression of hyperprolactinemia has
been reported in 32% (23), 33% (351), 35% (25) and up to 55%
of cases (26), but the great majority of these patients had
microadenomas. Therefore, even considering that natural
history might have a relevant role in the outcome of micro-
prolactinomas, it is less likely that macroadenomas would
spontaneously regress.
F. Authors’ personal experience
Because the possibility of inducing a long-lasting control
of hyperprolactinemia in the absence of continuing pharma-
cological treatment has profound consequences not only for
the patients’ compliance but also for pharmacoeconomics,
we started a project in January 1994 to analyze the remission
rate of hyperprolactinemia after withdrawal of cabergoline
therapy given as exclusive treatment for the disease. In the
absence of previous criteria for bromocriptine treatment
withdrawal, as described in Table 9, we chose to adopt two
conditions for the inclusion criteria for cabergoline with-
drawal: the normalization of PRL levels and the shrinkage of
the tumor on MRI. As a further precaution, once the patients
fulfilled our criteria, cabergoline treatment was continued for
another 12 months. Based on results in the literature on
bromocriptine and cabergoline withdrawal (Table 8), the
achievement of normoprolactinemia as the first inclusion
criterion was a mandatory requisite that does not require
further explanation. We also decided to consider the amount
of tumor shrinkage as a further criterion, because cytocidal
effects of bromocriptine have been previously shown (184)
and disappearance of prolactinomas during cabergoline
treatment has also been well documented (205, 206, 353, 354).
On this basis, we performed the analysis of the results di-
viding the patients with hyperprolactinemia achieving stable
normalization during cabergoline treatment into those hav-
ing tumor disappearance on MRI and those having a con-
sistent reduction of tumor mass, which we arbitrarily set at
at least 50% of baseline. An exclusion criterion was the in-
vasion of critical structures such as cavernous sinuses, optic
chiasm, III ventricle, etc.; thus, patients with at least 50%
shrinkage of their tumors that invaded critical structures
were excluded from treatment withdrawal. Interestingly, al-
though patients with negative MRI had a lower rate of re-
currence than those with visible adenomas, more than half
of the patients showing remnant tumors on MRI had per-
sistent normoprolactinemia after drug withdrawal. This
suggests that some of these patients have abnormalities on
MRI other than prolactinomas, such as small nonfunction-
ing lesions, fibrotic scar, or other nontumoral abnormal-
ities (incidentalomas).
In the first analysis of our series of patients, there were no
cases of recurrence of hyperprolactinemia after 3 yr of with-
drawal. Because the number of patients with an available
follow-up after 36 months was still limited compared with
the entire series (97 of 200), to provide further information on
this topic, we have extended the follow-up of the 200 patients
enrolled in the study of 2003 (98) up to 90 months. Table 9
provides details of the population at this second analysis. Of
the initial 200 patients, 14 patients were lost at follow-up, and
26 women became pregnant during the study: all these 40
patients were in remission of hyperprolactinemia at the time
of study exit. Remission rate after prolonged discontinuation
of cabergoline treatment (median follow-up, 72–90 months)
was 68.4% in patients with nontumoral hyperprolactinemia,
51.8% in patients with microprolactinomas, and 52.5% in
patients with macroprolactinoma. However, as already dem-
onstrated by the first analysis (98), the highest remission rates
were found in patients with nontumoral hyperprolactinemia
or with either microprolactinomas or macroprolactinomas
that had disappeared on MRI during cabergoline therapy
(Fig. 7). The 7-yr Kaplan-Meier estimation of recurrence
showed that the remission rates in the patients with small
FIG. 6. Cox regression analysis indicating that the nadir value of
maximal tumor diameter during cabergoline treatment is the best
predictor of hyperprolactinemia afterwithdrawal (2 12;P 0.001).
E, Individual results in the 200 patients of last PRL levels after
withdrawal correlated with nadir maximal diameter during treat-
ment. Data are derived from Ref. 98.
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remnant tumors on MRI were much lower, i.e., 20% in mi-
croprolactinomas and 0% in macroprolactinomas (Fig. 7).
Importantly, at the last follow-up (48–90 months after caber-
goline withdrawal), no recurrence of hyperprolactinemia
was documented in the patients who had no evident tumor
on MRI later than 36 months.
G. Practical implications and approaches
To avoid unnecessary treatment, cabergoline withdrawal
can be performed in patients with normoprolactinemia after
at least 2 yr of treatment and when the MRI demonstrates
complete disappearance of the tumor. If small remnants are
still visible, we do not suggest withdrawing treatment. Al-
ternatively, in patients with microprolactinomas, treatment
can be withdrawn, but the higher recurrence rate should be
considered and a more careful follow-up performed. In any
case, the follow-up should be very strict during the first year
after withdrawal, because the recurrence rate is highest dur-
ing this period. It can subsequently be tailored on the basis
of an individual patient’s history and severity of disease.
Because pregnancy and menopause are both physiological
events associated with remission of hyperprolactinemia,
these events should receive special attention with regard to
the need for continuing therapy.
IX. Pregnancy
The management of prolactinomas in pregnant women
can be complex. Three major issues arise in the treatment of
prolactinomas in pregnancy: 1) the effect of the pregnancy on
the prolactinoma; 2) the effects of the dopamine agonist on
early fetal development occurring before a pregnancy is di-
agnosed; and 3) the safety and efficacy of dopamine agonists
after reintroduction for symptomatic tumor growth.
A. Effect of pregnancy on prolactinoma growth
During pregnancy, estrogen stimulates PRL synthesis and
secretion and promotes lactotroph cell hyperplasia (355).
PRL levels in the maternal circulation rise throughout normal
pregnancy, reaching a mean concentration of 150 ng/ml at
term (356, 357). Autopsy studies showing lactotroph cell
hyperplasia during pregnancy have been corroborated in
vivo by MRI scans showing a gradual increase in pituitary
volume over the course of gestation, beginning in the second
month, peaking the first week postpartum, and achieving a
FIG. 7. Kaplan-Meier estimation of recurrence rates over 7 yr. Re-
mission rates in patients with small remnant tumors evident on MRI
are much lower than those without tumor remnants or those with
nontumoral hyperprolactinemia (NTH). , NTH; F, microprolacti-
nomas without tumor remnant; E, microprolactinomas with tumor
remnant; f, macroprolactinomas without tumor remnant; , mac-
roprolactinomas with tumor remnant. The difference among the
Kaplan-Meier curves is significant (P  0.0001).
TABLE 9. Remission rates of hyperprolactinemia after at least 48 months of cabergoline withdrawal
PRL levels (g/liter) Maximal tumor diameter (mm) Median time of
follow-up (months)Baseline Nadir Baseline Nadir
Nontumoral hyperprolactinemia
Recurrence (n  6) 70.4  5.2 9.6  2.6 Negative Negative 18
Remission (n  13) 74.1  8.1 1.8  0.8 Negative Negative 90
Pregnancy (n  3)a 51.7  3.0 1.5  0.5 Negative Negative 48
Lost at follow-up (n  3) 59.3  0.6 1.2  1.0 Negative Negative 24
Microadenomas
Recurrence (n  39) 178.1  35.6 8.9  5.9 6.9  1.4 2.5  2.2 12
Remission (n  42) 143.5  45.4 4.2  3.3 6.5  1.8 1.0  1.6 72
Pregnancy (n  18)a 167.5  64.6 4.0  4.8 7.3  1.6 0.6  1.4 36
Lost at follow-up (n  6) 173.3  48.9 4.7  3.0 7.3  1.9 2.6  2.1 42
Macroadenomas
Recurrence (n  39) 1131  1147 6.3  3.3 18.3  5.6 3.4  3.8 24
Remission (n  21) 814  2046 4.0  1.9 16.0  8.3 1.1  2.1 72
Pregnancy (n  5)a 481  210 2.8  1.2 15.0  4.2 0.8  1.9 24
Lost at follow-up (n  5) 400  209 5.2  2.9 14.3  3.7 0  0 36
Inclusion criteria for cabergolinewithdrawalwere as follows: 1) serumPRLnormalization (25g/liter inwomen or 15g/liter inmen) during
cabergoline treatment; 2) disappearance of the tumor or reduction in tumor size by 50% or more from baseline; to minimize the risk of errors
in reading MRI scans, treatment was continued before stopping in all patients for another 12 months after fulfilling the specified withdrawal
criteria; 3) follow-up after withdrawal of at least 24 months to characterize early and delayed recurrences. Exclusion criteria for cabergoline
withdrawal were as follows: 1) serum PRL levels above 25 g/liter in women or 15 g/liter in men during cabergoline treatment; 2) tumors
increasing in size during cabergoline treatment or not decreased in size by 50% or more from baseline; tumors whose outer border was 5 mm
or less from the optic chiasm; tumors with MRI evidence of invasion of one or both cavernous sinuses or any other critical area.
a All women who became pregnant during the study were excluded from further analysis. Data are shown as mean  SD. 2/Fisher’s exact
tests were used to analyze proportions. Data are derived from an extension study of Ref. 98.
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final mean height of 11.8 mm (358–360). After delivery, the
gland rapidly involutes and returns to its normal size by 6
months postpartum (358, 359).
Reports of enlargement of prolactinomas associated with
pregnancy began over 30 yr ago, shortly after the introduc-
tion of bromocriptine as an effective medical therapy for
these tumors (334, 361–369). Early on, many of the symp-
tomatic patients underwent surgery for visual defects (334,
363, 365, 367). However, the observation was soon made that
in those who were managed without surgery, symptoms
resolved shortly after parturition (334, 364, 366, 368). The
enlargement of macroadenomas during pregnancy is there-
fore due to two factors: 1) discontinuation of the dopamine
agonist that had caused the tumor to shrink; and 2) the
stimulatory effect of the high estrogen levels produced by the
placenta.
The potential for the enlargement of a prolactinoma during
pregnancy is highly dependent upon two factors: its size, and
the patient’s history of prior radiotherapy or surgery. A total
of five studies have compiled data analyzing the risk of
symptomatic tumor enlargement in pregnant women with
prolactinomas, divided according to their status as micro- or
macroprolactinomas (370–374) (Table 10). These studies do
not include case reports, only patients who were part of a
larger subset being evaluated. According to these data, the
risk of symptomatic tumor enlargement for microadenomas
is low. Only 12 of 457 pregnancies (2.6%) were complicated
by symptoms of tumor enlargement (headaches and/or vi-
sual disturbances). Surgical intervention was not required in
a single case. Medical therapy with bromocriptine was in-
stituted in five individuals, which was followed by the res-
olution of their symptoms. A few of these studies assessed
the possibility of asymptomatic tumor growth by CT or MRI
scans. In one review, 11 of 246 women (4.5%) with micro-
prolactinomas demonstrated asymptomatic tumor growth
(372). Another series documented tumor growth at similar
low frequency in two of 41 microprolactinomas (5%) (373).
The risk of tumor enlargement in pregnancy is substan-
tially greater for patients with macroprolactinomas. It is par-
ticularly high in women who have not undergone prior sur-
gery or radiotherapy for their macroprolactinomas.
According to the series included in Table 10, 45 of 142 preg-
nancies (31%) were complicated by symptoms of tumor en-
largement (headaches and/or visual disturbances). Surgical
intervention was undertaken in 12 of these cases (8.5%).
Seventeen symptomatic patients with macroadenomas (who
had not undergone prior surgery or radiotherapy) received
medical therapy with bromocriptine, leading to resolution of
their symptoms. Asymptomatic growth of macroprolactino-
mas was demonstrated by CT or MRI scans in a further four
of 45 individuals (8.9%) in one series (372) and in a further
four of 23 (17%) in another series (373). A total of 140 women
with macroadenomas have been identified who have un-
dergone surgery or radiation before pregnancy. In these in-
dividuals, the risk to tumor enlargement was low (2.5%).
Thus, the overall risk of clinically significant enlargement
of microprolactinomas is low. It is similarly low for macro-
prolactinomas that are surgically resected or irradiated pre-
gestationally (5%). There is a moderate risk of clinically sig-
nificant tumor enlargement for macroprolactinomas that
have only been treated with dopamine agonists pregesta-
tionally (31%). These data serve as the basis for management
recommendations that are suggested below.
It should be emphasized that surgery was undertaken in
many of these symptomatic women (25–50%) in the earliest
studies before it was recognized that bromocriptine could
reduce tumor size. Several reports have now documented the
successful and safe use of bromocriptine and cabergoline to
control tumor growth and alleviate visual symptoms during
pregnancy, without adverse effects on the infants (371, 372,
375–382).
B. Effects of dopamine agonists on fetal development
As discussed previously, hyperprolactinemia is usually
associated with anovulation and infertility; correction of the
hyperprolactinemia with dopamine agonists restores ovula-
tion in about 90% of cases. Most patients with prolactinomas
that come to clinical attention will require treatment of hy-
perprolactinemia to ovulate and conceive. Therefore, under
these circumstances, the fetus is likely to be exposed to one
of these drugs for at least 3–4 wk of gestation, until a preg-
nancy test can verify conception and allow discontinuation
of the medication. Because all of the dopamine agonists have
been shown to cross the placenta in humans and/or animals,
it is advised that fetal exposure to the dopamine agonists be
limited to as short a period as possible. The following section
presents data regarding the effects of dopamine agonists
when used in the early stages of gestation and when used
throughout the pregnancy.
The use of bromocriptine, when it is taken for only the first
few weeks of gestation, has not been associated with an
increase in the rates of spontaneous abortions, ectopic preg-
nancies, trophoblastic disease, multiple pregnancies, or con-
genital malformations in a very large number of pregnancies
(Table 11) (383, 384). Long-term follow-up studies of 64 chil-
dren, between the ages of 6 months and 9 yr, who were born
to mothers who took bromocriptine for a limited duration in
early pregnancy have shown no adverse effects on childhood
development (385). There is less data available on the effects
of continuous bromocriptine (used throughout gestation) on
fetal/infant development. An analysis of the infant outcomes
of approximately 100 women who used bromocriptine
throughout gestation revealed abnormalities in two infants,
TABLE 10. Effect of pregnancy on prolactinomas
Total no.
of patients
Symptomatic
enlargement
% Symptomatic
enlargement
No. requiring
surgery (%)
Microadenomas 457 12 2.6
Macroadenomas 142 45 31 12 (8.5%)
Macroadenomas, prior surgery or radiation 140 7 5
Data compiled from Refs. 370–374.
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one born with an undescended testicle and one with a talipes
deformity (386).
Few data are available on the safety of pergolide in
pregnancy. Detailed data on the safety of pergolide during
early gestation has only been reported in one woman
treated with pergolide for Parkinson disease (387). The
child of this pregnancy had no evidence of developmental
abnormalities. According to statements made in this re-
port, two major and three minor congenital abnormalities
were described among 38 pregnancies in women receiving
pergolide in premarketing studies, but a causal relation-
ship was not definitively established (387). The manufac-
turer of pergolide, Eli Lilly & Co. (Indianapolis, IN), re-
ports limited data on pregnancies in which the fetus was
exposed to pergolide but did find that 7.2% of pregnancy
outcomes resulted in spontaneous abortions, 7.2% in mi-
nor malformations, 14.3% in intentional abortions, 28.6%
in healthy infants, and 43.4% with no information avail-
able (388). This limited information seems sufficient to
recommend against the use of pergolide for a woman
desiring pregnancy.
Quinagolide does not appear to be safe during pregnancy.
Some early publications reported no detrimental effects on
pregnancy or fetal development in women who became
pregnant during treatment with quinagolide (327). However,
a recent review of 176 pregnancies, in which quinagolide was
maintained for a median duration of 37 d, reported 24 spon-
taneous abortions, one ectopic pregnancy, and one stillbirth
at 31 wk gestation (244). Furthermore, nine fetal malforma-
tions were reported in this group, including spina bifida,
Trisomy 13, Down syndrome, talipes, cleft lip, arrhinen-
cephaly, and Zellweger syndrome (244). Therefore,
quinagolide should also not be used if pregnancy is desired.
Experience with the use of cabergoline in pregnancy is
accumulating. Data on exposure of the fetus or embryo dur-
ing the first several weeks of pregnancy have been reported
in just over 350 cases, and such use has not shown an in-
creased percentage of spontaneous abortion, premature de-
livery, multiple pregnancy, or congenital abnormalities (204,
349, 373, 389–392). No alterations in the newborns’ weights
were observed (204, 373, 389–391). Short-term follow-up
studies of 107 infants born to mothers who used cabergoline
during pregnancy indicate normal neonatal physical and
mental development (391).
Taken together, the following may be concluded with
respect to the use of a dopamine agonist to facilitate ovu-
lation and fertility. Bromocriptine has the largest safety
database and has a proven safety record for pregnancy.
The database for the use of cabergoline in pregnancy is
much smaller, but there is no evidence at present indicat-
ing that it exerts deleterious effects on pregnant women.
The incidence of malformation in their offspring is not
greater than in the general population. For the woman who
is intolerant to bromocriptine and who is doing well with
cabergoline, continuation of cabergoline for facilitating
pregnancy appears to be reasonable. Although the safety
databases for pergolide and quinagolide are limited, the
number of abortions and malformations associated with
the reported pregnancies raises serious concern. There-
fore, quinagolide and pergolide should not be used when
fertility is desired, and all premenopausal women treated
with these medications should be apprised of these data.
If reinstitution of a dopamine agonist is needed later in
gestation to control tumor growth, bromocriptine is fa-
vored over the other dopamine agonists due to greater
experience with this drug in this setting.
C. Recommendations for management of prolactinoma in
pregnancy
The optimal management approach for a woman with a
prolactinoma who desires pregnancy may depend on tumor
size and individual tumor characteristics. Irrespective of
these factors, the risks and benefits of surgical vs. medical
therapy should be explained in detail to each patient.
A hyperprolactinemic woman harboring a microprolacti-
noma has three options to restore fertility: a dopamine ag-
onist alone, transsphenoidal selective adenomectomy, or
bromocriptine after surgery or irradiation. Pregnancy can be
achieved in 80–85% of women with microadenomas treated
with either bromocriptine or surgery (393–396). Transsphe-
noidal surgery of microprolactinomas is curative (long-term)
TABLE 11. Effect of bromocriptine on pregnancies
Bromocriptine (n) Bromocriptine (%) Normal population (%)
Pregnancies 6239 100 100
Spontaneous abortion 620 9.9 10–15
Terminations 75 1.2
Ectopic 31 0.5 0.5–1.0
Hydatidiform moles 11 0.2 0.05–0.7
Deliveries (known duration) 4139 100 100
At term (38 wk) 3620 87.5 85
Preterm (38 wk) 519 12.5 15
Deliveries (known outcome) 5120 100 100
Single births 5031 9.3 8.7
Multiple births 89 1.7 1.3
Babies (known details) 5213 100 100
Normal 5030 96.5 95
With malformations 93 1.8 3–4
With perinatal disorders 90 1.7 2
Data are derived fromRef. 384. Bromocriptine (n) refers to the number of patients treated with bromocriptine who experience the event listed
in the first column. Bromocriptine (%) refers to the percentage of patients treated with bromocriptine who experience the listed event. Normal
population (%) refers to the percentage of the normal population that experiences the listed event.
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in approximately 60% of cases; nevertheless, it entails mor-
bidity and mortality, albeit at very low rates (see Section
III.G). For patients with microprolactinomas (or intrasellar
macroprolactinomas), bromocriptine or cabergoline therapy
is generally preferred to surgery because it is safe for the fetus
when discontinued early in gestation and poses only a very
low risk of tumor enlargement for the mother. Rare patients
who remain infertile with failure to respond to either mo-
dality may need additional hormonal therapy to facilitate
ovulation, such as clomiphene citrate plus human chorionic
gonadotropin, pulsatile GnRH therapy, or recombinant go-
nadotropins (334, 397–401). Although radiotherapy has been
advocated for patients with microadenomas before bro-
mocriptine-induced pregnancy, this strategy is unwarranted,
because the risk of tumor enlargement without radiotherapy
is much lower than the risk of known, long-term sequelae of
hypopituitarism associated with pituitary radiotherapy (108,
156, 157).
A patient with a microadenoma treated only with a do-
pamine agonist pregestationally should be carefully fol-
lowed throughout pregnancy. PRL levels do not always rise
during pregnancy in women with prolactinomas, as they do
in normal women. Usually PRL levels rise over the first 6–10
wk after discontinuing bromocriptine and then do not in-
crease further (402). PRL levels may also not rise with tumor
enlargement (403). For these two reasons, periodic assess-
ment of PRL levels is not beneficial. Because of the low
incidence of tumor enlargement in microprolactinomas, rou-
tine periodic visual field testing is not cost effective. Visual
field testing and MRI scans should be performed, however,
in patients who develop visual changes or symptoms of mass
effects. If tumor enlargement occurs, reinstitution of a do-
pamine agonist is often successful in reducing the size; how-
ever, persistent visual defects may necessitate transsphenoi-
dal surgery or early delivery.
For the patient with a small intrasellar or inferiorly ex-
tending macroadenoma, bromocriptine is also favored as the
primary therapy. The likelihood that such a tumor will en-
large sufficiently to cause clinically serious complications is
probably only marginally higher than the likelihood in pa-
tients with microadenomas.
In a woman with a larger macroadenoma that may have
suprasellar extension, there is a 15–35% risk of clinically
serious tumor enlargement during pregnancy when only
bromocriptine is used. There is no clear-cut answer as to the
best therapeutic approach, and this has to be a highly indi-
vidualized decision that the patient has to make after a clear,
documented discussion of the various therapeutic alterna-
tives. The most conservative approach is to perform a
prepregnancy transsphenoidal surgical debulking of the tu-
mor. This should greatly reduce the risk of serious tumor
enlargement, but cases with massive tumor expansion dur-
ing pregnancy after such surgery have been reported (378).
After surgical debulking, bromocriptine is required to restore
normal PRL levels and allow ovulation. Although radiother-
apy before pregnancy, followed by bromocriptine, reduces
the risk of tumor enlargement to only 5%, it is rarely curative.
Radiotherapy may also result in long-term hypopituitarism
(see Section IV.F), so that this approach seems much less
desirable than transsphenoidal surgery plus bromocriptine.
A third approach entails administration of bromocriptine
continuously throughout gestation (404). The safety of the
last approach has not been established, but based on the
small number of cases cited earlier, it probably is not harmful
(395). Should pregnancy at an advanced stage be discovered
in a woman taking bromocriptine, the existing data are re-
assuring and would not justify therapeutic abortion. The
most common approach is just to stop bromocriptine after
pregnancy is diagnosed, as is done in patients with
microadenomas.
For patients with macroadenomas treated with bro-
mocriptine alone or after surgery or irradiation, careful fol-
low-up with 1-month to 3-month visual field testing is war-
ranted. Repeat scanning is reserved for patients with
symptoms of tumor enlargement and/or evidence of a de-
veloping visual field defect or both.
Should symptomatic tumor enlargement occur with any of
these approaches, reinstitution of bromocriptine is probably
less harmful to the mother and child than surgery. There
have been a number of cases reported where such reinsti-
tution of bromocriptine has worked quite satisfactorily, caus-
ing rapid tumor size reduction with no adverse effects on the
infant (see Section IX.B). Any type of surgery during preg-
nancy results in a 1.5-fold increase in fetal loss in the first
trimester and a 5-fold increase in fetal loss in the second
trimester, although there is no risk of congenital malforma-
tions from such surgery (405). Thus, bromocriptine reinsti-
tution would appear to be preferable to surgical decompres-
sion. However, such medical therapy must be very closely
monitored, and transsphenoidal surgery or delivery (if the
pregnancy is far enough advanced) should be performed if
there is no response to bromocriptine and vision is progres-
sively worsening.
X. Prolactinomas in Children and Adolescents
A. Epidemiology
Pituitary adenomas are less common in children than in
adults, but they become increasingly more frequent during
the adolescent years (406–408). Pituitary adenomas consti-
tute less than 3% of supratentorial tumors in children (406–
408) and 2.3–6% of all intracranial tumors treated surgically
(19, 20, 406–412). However, most published series included
patients with onset of symptoms before the age of 20 yr as
pediatric patients (19). The average annual incidence of pi-
tuitary adenomas in childhood has been estimated to be 0.1
per million children (413). Pituitary carcinomas are rare in
adults and extremely rare in children (414).
There appears to be a greater invasiveness of prolactino-
mas in children compared with adults (407, 412, 415). Mac-
roadenomas at presentation are more likely in boys than in
girls (20, 407, 416). In the series reported by Colao et al. (417),
microprolactinomas were more frequent in females (10 of 17),
whereas macroprolactinomas were slightly, but not signifi-
cantly, more frequent in males (7 of 9) than in females (7 of
17).
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B. Presentation
Prepubertal children generally present with a combination
of headache, visual disturbances, growth failure, and pri-
mary amenorrhea (Table 12). However, growth failure has
been reported to be common in some series (416, 418, 419),
but not others (17, 22). In fact, Colao et al. (417) found growth
arrest only in one male patient with microprolactinoma (4%),
whereas all the remaining 25 patients had normal heights,
and pubertal development was appropriate for their age.
Cannavo` et al. (420) reported short stature in three of 30
adolescents with either micro- or macroprolactinoma (10%).
Growth and pubertal development were reported to be nor-
mal also in a 16-yr-old boy with multiple endocrine neoplasia
type 1 (MEN 1) syndrome with a pituitary adenoma accom-
panied by mild elevation of PRL and GH that was identified
through family screening (421). In a reevaluation of the
young/adolescent patients with hyperprolactinemia admit-
ted to the University Federico II Hospital from January 1,
1995, to December 31, 2004, we found short stature in seven
of 50 patients (14%), five girls and two boys, and another two,
one girl and one boy, had their height below or at the 5th
percentile. As expected, the percentiles of height in the pa-
tients with extrasellar/invasive macroprolactinomas were
lower than in patients bearing smaller tumors (P  0.015
comparing microprolactinomas vs. extrasellar tumors; Table
12). Macroadenomas were slightly more frequent at diagno-
sis in boys than in girls (76.2 vs. 48.3%; P  0.09).
The most common symptoms of prolactinomas in the
peripubertal age range are those associated with deficiency
of the pituitary-gonadal axis. Menstrual irregularities in girls
are common in all types of pituitary adenomas, except those
causing Nelson’s syndrome (418). As in the adults (17), the
size of the prolactinomas is reported to correlate well with
baseline PRL levels (417). In 50 patients, we found a high
correlation between PRL levels and tumor volume (r 0.84;
P  0.0001) and PRL levels and body mass index (BMI) (r 
0.48; P  0.024). Weight gain has been reported to occur in
patients with hyperprolactinemia (17, 422–424) but has not
been described previously in children. However, among our
50 children, 23 had a normal BMI (25 kg/m2), 25 were
overweight (BMI, 25.1–30 kg/m2), and two were obese (BMI,
30 kg/m2). Headache and/or visual field defects were
common first symptoms in the majority of patients with
macroadenomas (417). This finding was confirmed in the
reevaluation of these 50 patients: in 28 of 29 girls, the first
symptoms were amenorrhea, primary or secondary, or oli-
gomenorrhea. The remaining girl, 10.5 yr old at diagnosis,
had a large tumor (volume, 1982.6 mm3; maximal diameter,
17.9 mm) that was diagnosed because of headache and bi-
lateral galactorrhea in a context of panhypopituitarism (Ta-
ble 12). In young patients, galactorrhea should be carefully
investigated on breast examination, because teenagers may
not voluntarily refer to it as a symptom, and frequently it is
not spontaneous (415). Cannavo` et al. also reported galac-
torrhea in 91% of their patients (420). In boys, the most
common symptoms were headache (15 of 21 patients) and
gynecomastia (12 of 21 patients).
Impairment of other pituitary hormone secretion was pre-
viously reported to occur in only a minority of patients at
diagnosis (417, 420) and in some patients hypopituitarism
developed after surgery. Our recent reevaluation allowed us
to confirm that pituitary deficiencies in the context of a mi-
croprolactinoma are very rare (4.7%), whereas deficiencies
are common in patients with macroadenomas with extrasel-
lar extension (77.8%; Table 12). Additionally, 33.3% of the
patients with enclosed macroadenomas presented with some
degree of pituitary deficiency. Reduction of tumor size by
TABLE 12. Presentation of prolactinomas in children and adolescents
Microadenomas Enclosedmacroadenomas
Extrasellar and/or
invasive macroadenomas
N 20 21 9
No. of girls/boys 15/5 11/10 3/6
Age at diagnosis (yr) 14.4  0.5 14.8  0.4 13.8  1.1
Height (percentile) 35.5  4.0 26.9  5.7 16.2  6.3
BMI (kg/m2) 24.4  0.5 26.1  0.4 27.6  1.2
Basal PRL levels (g/liter) 138.4  21.6 671.4  161.9 2123  279
Tumor volume on MRI (mm3) 113.0  15.1 1145  145 2826  330
Symptoms (%)
Amenorrheaa 53.3 (33.3/20) 72.7 (9.1/63.6) 66.7 (33.3/33.3)
Oligomenorrheaa 46.7 18.2 0
Gynecomastiab 100 55.6 16.7
Galactorrhea 42.8 60 33.3
Visual field defects 0 50 66.7c
Headache 33.2 80 66.7
Pituitary hormone defects (%)d
Isolated GH deficiency 4.7 5 0
Isolated TSH deficiency 0 0 0
Isolated ACTH deficiency 0 10 0
Multiple hormone deficiencies 0 20 77.8
Data represent the experience of the Department of Endocrinology and Oncology, University Federico II of Naples, reported as mean 
SEM or percentage.
a Calculated only in girls.
b Calculated only in boys.
c All boys.
d FSH and LH deficiency were not assessed.
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dopamine agonists or surgery may result in a restoration of
normal pituitary function (22, 425).
Lastly, the most frequent complication of hyperprolactine-
mia in adult patients is decreased BMD, resulting in osteo-
porosis in some patients (426–428). Di Somma et al. (191)
reported a more severe impairment of BMD in young male
patients compared with those in whom hyperprolactinemia
occurred at an older age. In 20 patients with hyperprolactine-
mia during adolescence, Colao et al. (429) found significantly
lower BMD values both in adult and in adolescent patients
with hyperprolactinemia than in their sex- and age-matched
controls and also lower BMD values, corrected for age, in the
adolescent patients with hyperprolactinemia than in the
young adult patients. This finding is confirmed in a large
cohort of patients (Fig. 8). In 22 patients all having a diagnosis
of prolactinomas before the age of 18 yr, the BMD at lumbar
spine was significantly lower than in age-matched controls
(0.78  0.06 vs. 0.96  0.02 g/cm2). Z-scores at lumbar spine
ranged from 0.8 to 3.5. The z-score was significantly
correlated with BMI (r  0.48; P  0.024) but not with PRL
levels or tumor volume.
During childhood, prolactinomas can also represent the
first tumor in MEN 1 syndrome. In two recently reported
juvenile patients (421), a 14-yr-old girl developed prolacti-
noma and manifested delayed puberty and growth arrest,
whereas a 16-yr-old boy was asymptomatic, as already com-
mented above.
C. Treatment strategy
As for adult patients, in the absence of complications re-
quiring immediate surgery, such as visual loss, hydroceph-
alus, or CSF leak, pharmacotherapy with dopamine agonists
should be considered the first-line treatment approach. How-
ever, surgery in children poses no additional risks compared
with surgery in adults. In children and adolescents, bro-
mocriptine has been used successfully by several investiga-
tors (19). In our series, bromocriptine at doses ranging from
2.5–20 mg/d orally, induced normoprolactinemia in 38.5% of
patients (417). Compliance issues and intolerance of side
effects were problems. Cabergoline, at doses ranging from
0.5–3.5 mg/wk orally, is also effective in adolescent patients
with large tumors and symptoms of tumor expansion. In our
cases, cabergoline induced normalization of PRL levels in all
but three cases, and in two of those three PRL levels were
reduced by more than 95%. Overall, cabergoline was much
better tolerated than bromocriptine. Twelve of our 50 pa-
tients (one with enclosed macroprolactinoma and 11 with
microprolactinoma) achieved the disappearance of the tu-
mor, so they were withdrawn from treatment according with
our protocol.
As shown in Fig. 9, PRL normalization was followed by an
increase in BMD at L1-L4, and osteocalcin levels (from 3.0
0.2 to 7.9  0.3 g/liter) were completely normalized.
Bisphosphonates probably should not be used in patients
who have not even achieved full bone maturity.
XI. Special Situations
A. Prolactinomas in males
A considerably greater proportion of males with prolacti-
nomas that come to clinical attention have macroprolactino-
mas, compared with women (17, 430). Although symptoms
of hypogonadism are still the most prevalent, symptoms due
to mass effects commonly serve as those that prompt medical
attention and lead to the diagnosis. A summary of 16 series
comprising 444 men with prolactinomas indicates that 77.9%
were impotent, 36.6% had visual field defects, 33.8% had
partial or complete hypopituitarism, 29.1% complained of
headaches, and only 10.9% had galactorrhea (60, 64, 75, 85,
114, 115, 431–441). Thus, about one third of men have symp-
toms due to tumor size.
Although it has been speculated that gender-specific dif-
ferences in tumor size may be related to a delay in diagnosis
in men (440), this theory is irreconcilable with data regarding
the infrequency of tumor growth in studies evaluating the
natural history of these tumors, as previously described.
There are some clinical and pathological data which indicate
that proliferative activity and tumor aggressiveness are
greater in prolactinomas from men compared with those
from women (21, 442). The molecular basis of these differ-
ences has not been determined.
Data on the efficacy of medical therapy in the treatment of
hyperprolactinemia in men are still limited, with few studies
comparing results in men vs. women (21, 191, 431, 436, 437,
440–445). The only prospective analysis evaluating differ-
ences in treatment efficacy between males and females found
FIG. 8. BMD and Z-scores at the lumbar spine (L1–L4).E, Individual
adolescent patients of the series studied in Naples at the University
“Federico II”. Boxes refer to sex- and age-matched controls.
FIG. 9. Rise in BMD Z-scores 2 and 4 yr after treatment with caber-
goline in 22 adolescent patients.
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that normalization of PRL after 6-month treatment with
cabergoline in 219 patients (145 females, 74 males) was sim-
ilar in women and men (17). As expected, successful treat-
ment was greater in patients with microprolactinomas than
in those with macroprolactinomas. In a retrospective study
of 455 patients treated with cabergoline, which included 102
men, the male patients were less likely than females to
achieve normoprolactinemia (75% vs. 90%) (204). However,
when considering the fact that the large majority of males in
this study had macroprolactinomas (86 for males vs. 38% for
females), gender did not have an independent influence on
success of treatment. In a subset analysis that only included
microprolactinomas, normalization of PRL was similar in
males and females (92 vs. 93%, respectively). On the other
hand, Pinzone et al. (444) determined in a retrospective study
that a similar percentage of their medically managed patients
(n  46) achieved a normalization of serum PRL.
Recovery from sexual dysfunction is possible with medical
therapy when normoprolactinemia is achieved, although
it is not universal and is dependent upon recovery of
adequate testosterone secretion. In a series of male patients
treated for up to 24 months with cabergoline, PRL levels
normalized in 75.6% of patients with macroadenomas and
in 80% of those with microprolactinomas (425). The max-
imal tumor diameter was reduced by 73.7  22.6% in
macro- and 72.8  28.3% in microprolactinomas. In this
study, testosterone levels normalized in 68.6% of patients.
Sperm volume and count normalized in all patients who
achieved normal testosterone levels, whereas sperm mo-
tility normalized in more than 80% (425). Nocturnal penile
tumescence (abnormal in 96.7% of patients at baseline)
normalized in 60.6% of the patients who achieved normal
PRL levels, but normalized in only 7.7% of patients who
remained hyperprolactinemic (446). Other studies have
shown a significant increase of number, motility, forward
progression, and normal morphology of sperm after PRL
normalization with bromocriptine, quinagolide, or caber-
goline treatment (192, 231). Use of cabergoline may facil-
itate more rapid improvement in the number and the
motility of sperm compared with use of bromocriptine
(192). More recent reports also confirm the beneficial ef-
fects of cabergoline treatment on the number of erectile
events and the recovery of semen quality in men with
prolactinoma (425, 446).
These data demonstrate that medical therapy, particularly
with cabergoline, is effective and safe in men with prolacti-
noma and can be successfully used as primary therapy even
in men bearing large macroprolactinomas. For men who
remain hypogonadal despite normalization of PRL, or for
men who do not achieve normoprolactinemia using maximal
doses of dopamine agonists, testosterone replacement
should be considered. Exogenous testosterone has the po-
tential to further increase PRL levels by aromatization to
estradiol; however, the frequency of this phenomenon is not
known (331, 447).
B. Prolactinomas in multiple endocrine neoplasia
Prolactinomas occur in about 20% of patients with MEN
1 and represent the most frequent type of pituitary adenoma
observed in this syndrome (448–450). There is evidence to
suggest that prolactinomas arising in patients with MEN 1
behave more aggressively than those that develop sporadi-
cally (448, 450). This issue was specifically addressed in the
France-Belgium multicenter study of 136 individuals with
MEN 1 harboring pituitary adenomas (450). Of the 136 ad-
enomas, prolactinomas accounted for 63% of all tumor types.
Compared with a control group consisting of individuals
with sporadic pituitary adenomas, prolactinomas in patients
with MEN 1 were larger and more aggressive at presentation.
For example, macroprolactinomas were more frequent in
MEN 1 patients than in non-MEN 1 subjects (84 vs. 24%), and
a high proportion of the MEN 1 prolactinomas were classi-
fied as invasive (24%). Over a median of 11.4 yr of follow-up,
the response to treatment was less satisfactory in the MEN
1 adenomas, with PRL level normalization achieved in 44%
of MEN 1 cases compared with 90% in sporadic cases. Al-
though it is uncertain whether the two groups compare with
respect to specific mode of therapy employed or the aggres-
siveness of their treatment regimens, these data suggest that
prolactinomas in MEN 1 may be relatively more resistant to
treatment. In general, the treatment strategy for prolactino-
mas in patients with MEN 1 does not differ from that for
sporadic prolactinomas. However, in light of the above data,
treating physicians should be aware of the potential need for
more intensive pharmacological therapy or the use of mul-
tiple therapeutic modalities to achieve satisfactory outcomes.
C. Giant prolactinomas
Giant prolactinomas are traditionally defined as PRL-
secreting adenomas greater than 4 cm in diameter and/or
those with more than 2 cm of suprasellar extension (77,
451–454). The exact prevalence of giant prolactinomas is not
known for certain, but two recent retrospective analyses of
prolactinomas at single institutions indicate that they are
uncommon, reporting prevalences of 0.5 and 4.4% among all
pituitary tumors (78, 455). Because of their rarity, relatively
few series are available describing treatment outcomes, al-
though many individual case reports have been documented
in the literature.
Giant prolactinomas are usually associated with very high
serum PRL concentrations, in the range of 20–100,000 ng/ml
when measured with two-site monoclonal immunoradio-
metric or chemiluminometric assays (77, 451, 456). Occasion-
ally, these assays will report inaccurately that PRL concen-
trations are normal or only mildly elevated, due to a
phenomenon referred to as the “hook effect” (457–459). This
effect occurs when hormone concentrations are exceedingly
high, causing independent saturation of binding sites on both
antibodies and interference with antibody-antigen-antibody
sandwich formation. Because the capture antibody is fully
occupied, the signal antibody remains in the liquid phase
and, as a result, becomes discarded during the washing step
of the assay protocol. The remaining weak signal on the solid
phase is falsely indicated as corresponding to a low hormone
concentration. The presence of the hook effect can be deter-
mined by measurement of PRL at 10- or 100-fold dilutions.
Failure to recognize this effect has led to misdiagnoses of
giant prolactinomas or large macroprolactinomas as non-
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functioning pituitary adenomas with mild hyperprolactine-
mia representing stalk disruption and, consequently, also led
to unnecessary neurosurgical intervention (460–463).
Giant prolactinomas represent a special management and
treatment situation for two reasons. First, in some circum-
stances, the therapeutic goals for these tumors may differ
from those held for more common micro- or smaller mac-
roprolactinomas. Second, specific complications may arise
during the treatment of giant prolactinomas that may alter
initial therapeutic plans, requiring alternative or additional
modes of therapy. Although the therapeutic goals for most
micro- and macroprolactinomas include normalization of
hyperprolactinemia, restoration of eugonadism, and reduc-
tion in tumor size, these goals may not be realistic for all giant
prolactinomas. Because PRL levels must be reduced to near
normal levels to restore normal reproductive function, a re-
duction of 50% or even 90% (although substantial) may not
be great enough to restore sexual and reproductive function
in severe hyperprolactinemia. Rather, in those giant tumors
that are not responsive to dopamine agonist therapy, en-
croachment upon or invasion into critical neural structures
may represent the most pressing concern. Furthermore, in
some situations, particularly in long-standing tumors, sub-
stantial reduction of tumor size may not reverse visual field
defects or hypopituitarism, and a more feasible goal may be
prevention of further growth. The benefits of any form of
treatment designed to achieve these goals must be balanced
against risks associated with the specific therapy (464).
Patients with giant prolactinomas can develop pituitary
apoplexy if their tumors do not reduce in size substantially
with a chosen form of therapy. In addition, rapid size re-
ductions in large prolactinomas that are highly sensitive to
dopamine agonist therapy can precipitate CSF rhinorrhea
(254, 257–259, 455). Both of these complications may require
timely surgical intervention and correction, although this
may not obviate the need for further medical and/or radio-
therapy postoperatively.
The absolute indications for surgical intervention in pa-
tients with giant prolactinomas are the same for all prolacti-
nomas and include continued tumor growth on medical ther-
apy, acute neurological defects that do not respond rapidly
to medical therapy, and unstable pituitary apoplexy. Surgical
cure is not a realistic attainable goal for giant prolactinomas,
but tumor debulking may be necessary in the aforemen-
tioned specific situations.
Surgical cure rates have been reported in a limited number
of patients with giant pituitary tumors operated via the trans-
sphenoidal, craniotomy, and combined transsphenoidal-cra-
niotomy routes. Mohr et al. (452) described an exceptionally
high hormonal improvement in a cohort of 14 patients with
giant prolactinomas who underwent transsphenoidal sur-
gery. In this series, it was reported that only six of 14 patients
required bromocriptine for persistent hyperprolactinemia
postoperatively. However, it was not explicitly stated
whether normoprolactinemia (or mild hyperprolactinemia)
was in fact attained or sustained in the eight other patients,
so whether these eight individuals actually achieved remis-
sion or cure, or perhaps opted for radiotherapy, cannot be
ascertained from their data. There has been no other series
restricted to patients with giant prolactinomas treated with
surgery alone that has reported hormonal cure or complete
resection of tumor mass in a single patient. Ciric et al. (465)
reported that of 14 cases of giant prolactinoma operated
transsphenoidally, “such a removal [was] difficult or impos-
sible,” although specific figures were not detailed. Guidetti
et al. (466) found that normalization of PRL levels was not
achieved in any of six patients operated for giant prolacti-
nomas. Of four patients reported by Davis et al. (451) and two
reported by Murphy et al. (77), none had return of PRL to
normal levels postoperatively, and all had significant resid-
ual tumor after surgery.
The morbidity and mortality rates associated with surgical
intervention are considerably higher for giant pituitary ad-
enomas than for smaller, noninvasive adenomas, especially
those that require transfrontal approaches. Complication
rates specific to surgery for giant prolactinomas are not avail-
able, but may be estimated on the basis of rate complications
found after surgical resection of giant pituitary adenomas in
general. Of 16 cases of giant pituitary adenoma operated via
craniotomy by Symon et al. (454), three died in the immediate
postoperative period, and two others died within 6 months
of surgery. In a series of 77 patients operated upon by Pia et
al. (453), there were eight operative deaths and considerable
morbidity, including increased visual loss in four, oculomo-
tor disturbances in eight, diabetes insipidus in 15, mental
deterioration in 14, and CSF fistulas in five. Fewer compli-
cation rates are reported in more recent series that use trans-
sphenoidal approaches, although they are still higher than
those observed in other surgical series. For example, Mohr et
al. (452) reported a transsphenoidal operative mortality of
5.2%, primarily resulting as a consequence of postoperative
hematomas. The risk of significant organic brain syndrome
in this series of transsphenoidal surgeries was 3% and that
of permanent diabetes insipidus was 6.5% (452). Even the
most recent surgical series still report significant complica-
tion rates. In a series of 92 giant pituitary tumors operated on
via the transsphenoidal or combined transsphenoidal/trans-
frontal routes, surgical morbidity was 3.3%, CSF leak was
5.4%, and worsening vision on follow-up was 7.6% (467).
Another recent surgical series of 43 giant pituitary adenomas
reported by Garibi et al. (468) found a mortality of 4.7%, with
permanent diabetes insipidus in 9.3% and meningitis with
CSF fistula formation in 14.0%.
Thus, surgery for giant prolactinomas can be successful in
debulking tumors but actual cure is uncommon in almost all
series. However, complication rates are high, with mortality
rate ranging from 3.3% (467) to 31.2% (454) and the major
morbidity rate ranging from 10% (452) to 62% (454).
Radiotherapy has been used as adjunctive therapy in pa-
tients with giant prolactinomas; however, the effects of ra-
diotherapy alone are difficult to discern from the effects of
either prior surgery or concomitant medical therapy. One
study of four giant prolactinomas that were treated initially
with conventional radiotherapy (41.4–50 Gy) before medical
therapy reported that no patient had been endocrinologically
or radiologically cured with radiotherapy after an interval
varying from 1 month to 7 yr (before any medical therapy)
(456). Nevertheless, radiotherapy may be indicated for those
who demonstrate absolutely no response to dopamine ago-
nists or whose tumors were documented to actually grow on
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dopamine agonists or after incomplete surgical removal
(469).
Normalization of PRL and even radiological disappear-
ance of tumor is possible in some giant prolactinomas. Data
on the efficacy of medical therapy for giant prolactinomas
has been reported in seven series consisting of at least two
patients (Table 13). Some of these patients underwent prior
surgery or radiotherapy, which in most cases was associated
with little change in PRL levels or tumor mass. Of patients
reported in these series who were treated with either bro-
mocriptine or cabergoline, 32 of 49 (65%) achieved a normal
PRL level, and 29 of 45 (64%) experienced at least 50% re-
duction in tumor size. In the 35% of patients who did not
normalize PRL levels on medical therapy, partial responses
(PRL reductions 95%) were possible in many cases.
Because of the excellent potential results with dopamine
agonists and largely poor results of surgery in most patients,
the authors recommend dopamine agonists as initial therapy
for patients with giant prolactinomas and reserve surgery for
those patients who demonstrate inadequate responses to
medical therapy. Even if subsequent surgery is necessary for
tumor debulking, it rarely is curative, and a dopamine ag-
onist is usually necessary for treatment of the hyperpro-
lactinemia. In some extreme cases, complete tumor removal
may not be achievable by any means, and control of further
tumor growth may be acceptable. Given the relatively high
complication rates associated with surgery in these patients,
it is important to balance benefits of therapy with potential
complications. Whether surgery should be considered for
removal of a shrunken tumor during dopamine agonist treat-
ment is not established. Some tumors become fibrotic after
treatment with a dopamine agonist, and, as discussed pre-
viously, tumor removal has been found to be impaired in
some series (84, 85) but not others (72, 86, 87). However,
because complete surgical removal is rarely achieved and
dopamine agonists will still be necessary for controlling the
hyperprolactinemia, there seems to be little reason for sur-
gical intervention if the tumor mass has been reduced to a
sufficient size that neurological symptoms have been atten-
uated. Reduction in dopamine agonist doses may be possible
in patients taking large doses of dopamine agonists after
normoprolactinemia has been achieved and sustained for a
duration sufficient enough to ascertain a reasonable chance
for success. Successful dopamine agonist withdrawal has
been reported in a few patients. However, when therapy is
discontinued, the prolactinoma may return to its original
size, often within days to weeks. This potential return to
pretherapy size dictates extreme caution when withdrawing
dopamine agonists in giant prolactinomas, because rapid
tumor expansion may produce more severe clinical symp-
toms than slow tumor enlargement.
D. Malignant prolactinomas
Malignant prolactinomas are rare tumors. Their exact in-
cidence is not known for certain, but overall pituitary car-
cinomas represent less than 0.5% of symptomatic pituitary
tumors (470). Approximately 40 cases of malignant prolacti-
noma have been published in the English literature (286, 303,
320, 322, 471–497). Most commonly, malignant prolactino-
mas are indistinguishable from invasive macroadenomas at
presentation (498). The diagnosis of pituitary carcinoma can
only be made upon demonstration of metastatic spread; re-
liable distinction between carcinoma and adenoma cannot be
made on the basis of standard histological criteria (499). At
this time, there are no methods to accurately identify those
invasive pituitary tumors most likely to metastasize, thus
permitting early aggressive treatment before progression to
pituitary carcinomas (499).
Knowledge of the natural history of malignant prolacti-
nomas may be helpful for disease management. Typically,
the primary tumor is treated with medical, surgical, and/or
radiation therapy, followed by a long latency (years) before
recurrence or progression of residual tumor occurs and me-
tastases become apparent (489, 498, 500). Less commonly, a
malignant prolactinoma will exhibit early aggressive behav-
ior with multiple recurrences and early development of me-
tastases (489). Once metastases are diagnosed, survival is
usually very short, with a mean survival time of approxi-
mately 10 months (488). However, prolonged, asymptomatic
survival has been reported in a few patients (484, 488). Where
possible, dopamine agonists should be employed because
they can occasionally be effective in reducing the mass of
tumor (484, 488). Unfortunately, once craniospinal or sys-
temic metastases become obvious, therapeutic options are
limited in efficacy, and treatment is mainly palliative (498,
501). Surgery may be useful in debulking the lesion and
relieving local compressive effects (497). Chemotherapy with
somatostatin infusion, procarbazine, vincristine, cisplatine,
lomustine, carboplatin, and etoposide has been attempted
but as yet has not been demonstrated to be effective (322, 492,
496). A single case report detailed the dramatic response of
a patient with craniocervical metastases to the alkylating
agent, temozolomide (502), and other anecdotal reports of its
successful use have been described. However, with the ex-
ception of this case and isolated others (488, 502), there is no
evidence that either radiotherapy or chemotherapy prolongs
survival to any major extent (498).
XII. Experimental Therapy
A. Somatostatin analogs
Somatostatin analogs are widely used for the primary and
secondary treatment of somatotroph adenomas, for which
TABLE 13. Efficacy of dopamine agonist therapy in giant
prolactinomas
Series Ref. Drug No. ofpatients
Normal
PRL
50% tumor
reduction
Murphy 77 BRC 2 1 2
Davis 451 BRC 9 4 3
Grebe 456 BRC 4 3 NR
Saeki 601 BRC 10 7a 6
Minniti 602 CAB 4 3 1
Shrivastava 78 BRC 10 9 10
Corsello 455 CAB 10 5 7
TOTAL 49 32 (65%) 29 (64%)
BRC, Bromocriptine; CAB, cabergoline; NR, tumor shrinkage not
reported.
a One case required surgical intervention due to tumor growth
despite PRL normalization.
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they have been shown to be effective for the biochemical and
clinical control of acromegaly (503). The success of soma-
tostatin analog therapy for acromegaly is attributable both to
the high density of somatostatin receptor subtype 2 (SSTR2)
among somatotroph adenomas and the high affinity of the
available somatostatin analogs for this receptor subtype
(504). Somatostatin suppresses in vitro PRL secretion from
some prolactinomas in culture (292, 505, 506). However, so-
matostatin and octreotide do not reduce serum PRL levels in
patients with prolactinomas (507, 508) and therefore have not
been useful therapy for these patients. Despite the ineffec-
tiveness of somatostatin and SSTR2 subtype-specific analogs
for the treatment of prolactinomas, the recent introduction of
novel variants of somatostatin analogs has opened the door
for the use of these agents in patients with prolactinomas
who are resistant to standard (dopamine agonist) medical
therapy.
In addition to their expression in pituitary somatotrophs,
multiple SSTR subtypes have been identified in the normal
pituitary, as well as in other types of pituitary adenomas,
including prolactinomas. The normal pituitary predomi-
nantly expresses SSTR1, -2, and -5 (509, 510). All five SSTR
subtypes have been found in human prolactinomas, with
SSTR5 exhibiting the highest level of expression among the
receptor subtypes, and SSTR3 and SSTR4 exhibiting minimal
expression (509–516). Although the abundance of the five
SSTR subtypes found in prolactinomas varies among differ-
ent studies, it appears, from both a quantitative and func-
tional perspective, that the dominant SSTR in human pro-
lactinomas is SSTR5 (504, 514).
Shimon et al. (504) compared the in vitro effects of SSTR2
vs. SSTR5 analogs in primary cultures of human prolactino-
mas. Although the clinically available somatostatin analogs,
octreotide and lanreotide, did not suppress PRL release from
these prolactinoma cell cultures, newer SSTR5 subtype-se-
lective analogs (BIM 23052 and BIM 23268) did suppress PRL
secretion by 30–40% in four of six prolactinomas, including
two tumors that exhibited dopamine agonist resistance. Ja-
quet et al. (514) confirmed the functional selectivity of the
SSTR5 agonist BIM 23268 in their in vitro study of 10 pro-
lactinomas, showing 26–90% inhibition of PRL release,
which correlated with the expression of SSTR5 transcripts.
However, the degree of PRL suppression afforded by BIM
23268 was no greater than that achieved by quinagolide, and
additive inhibitory effects of quinagolide plus BIM 23268
were not observed. Therefore, further in vitro and in vivo
testing of SSTR5 subtype-selective analogs will be necessary
to determine whether these agents will serve a useful role for
the treatment of patients with dopamine agonist-resistant
prolactinomas.
The novel compound SOM230 has a broad somatostatin
binding profile, exhibiting high-affinity binding to SSTR1, -3,
and -5. SOM 230 has a 40 times higher binding affinity to
SSTR5 receptors, compared with octreotide, thus providing
rationale for a trial of this agent in reducing PRL secretion in
prolactinomas. Hofland et al. (517) found that SOM230 was
more potent than octreotide in suppressing PRL secretion in
primary cultures from both mixed GH-PRL-secreting ade-
nomas and pure PRL-secreting adenomas. Murray et al. (518)
reported similar results in primary cultures of two human
prolactinomas (30–40%). These results suggest a potential
role for SOM230 for the treatment of dopamine agonist-
resistant prolactinomas, primarily in those showing a high
level of SSTR5 expression.
Finally, a number of chimeric compounds have been de-
veloped that contain structural elements of both somatosta-
tin and dopamine in a single molecule. These hybrid mole-
cules exhibit potent, selective agonist activity at both the
SSTR2 subtype receptor and the D2 receptor. The SSTR and
D2 receptors have been shown to heterodimerize in the pres-
ence of appropriate ligands, generating a hybrid receptor
that enhances the inhibitory activity of adenyl cyclase (519).
Although it is known that the two receptors colocalize in
pituitary cells, the specific intracellular signaling pathways
by which the hybrid receptors mediate GH and PRL sup-
pression have not been fully elucidated (520). As for SOM230,
these hybrid compounds were initially developed for the
potential use in patients with acromegaly resistant to the
clinically available somatostatin analogs and thus far have
primarily been tested in cell cultures of GH-secreting or
mixed GH-PRL-secreting adenomas (521–523). The chimeric
somatostatin-dopamine molecule BIM 23A387 produced a
73% inhibition of PRL in six mixed GH plus PRL-secreting
adenomas (523). The chimera was more effective in sup-
pressing PRL secretion than a SSTR2 subtype analog alone,
D2 receptor agonist alone, or the two combined. Jaquet et al.
(521) tested a number of these compounds for their ability to
suppress PRL secretion and found maximal PRL suppression
of 46 to 74%, all of which were greater than octreotide. This
study did not, however, report a direct comparison of the
PRL-lowering effects of these chimeric compounds to any of
the available dopamine agonists. Thus, results of preliminary
studies of SSTR-D2 receptor chimeric agonists support further
investigation of their effects in humans with prolactinomas.
B. Therapy directed against estrogen/estrogen receptor
Estrogen may play a role in the development and/or pro-
gression of a subset of lactotroph tumors. Estrogen stimu-
lates PRL secretion and mitogenesis in pituitary lactotrophs
in both in vitro and in vivo models (524). In addition to the
well-known lactotroph hyperplasia that develops during
pregnancy, several cases of lactotroph adenoma have been
reported in male-female transsexuals given pharmacological
doses of unopposed estrogen, emphasizing the proliferative
effects of estrogen on these cells (35, 525, 526). In human
prolactinomas, multiple estrogen receptor (ER) variants gen-
erated by alternative splicing are coexpressed with ER and
ER. One tumor-specific splice variant, 5delER, which has
been identified in human prolactinomas, potently induces
the activity of estrogen-responsive genes in the presence of
ER, and this increased activity could conceivably confer a
pathophysiological role in promoting estrogen-regulated tu-
mor proliferation and/or PRL secretion in some patients
(527, 528). It should be emphasized that epidemiological
analyses of women taking oral contraceptives or hormone
replacement therapy have not shown associations with es-
trogen and prolactinoma development. It is the authors’ the-
ory that estrogen may play a permissive role in the growth
of a subset of prolactinomas that may have acquired genetic
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defects in pathways involving estrogen signaling or action.
Thus, estrogen represents one of several pituitary growth
factors that may serve as a therapeutic target to inhibit hor-
mone secretion and cell growth.
Strategies aimed at inactivating the ER or modulating
estrogen signaling provide an experimental approach to
reduce PRL hypersecretion and control lactotroph adeno-
matous growth. Most of the studies investigating the ef-
fects of selective ER modulators (SERMs) on prolactino-
mas have been performed in cell cultures derived from rat
prolactinoma cell lines or human prolactinomas (529 –538).
However, the reported in vitro effects of tamoxifen and
raloxifene have been inconsistent from study to study,
precluding definitive conclusions on their potential use at
this time. Although several studies have shown inhibitory
effects of these agents on PRL secretion and cell prolifer-
ation, some have shown no effects, or even stimulatory
effects, in others. Two recent studies have shown differ-
ential effects of tamoxifen and raloxifene on PRL secretion
(539) and cell proliferation (540). It is possible that the
discordant findings reported in studies involving SERMs
are due to variations in SERM dosages, duration of treat-
ment, and differences in the molecular behavior/charac-
teristics of individual tumors. Fulvestrant, a new type of
ER antagonist devoid of any agonist activity that binds to,
blocks, and degrades the ER (541), has been shown to have
PRL-reducing and antiproliferative effects in experimental
models (540, 542). For example, Heaney et al. (542) found
that the administration of fulvestrant to rats with sc so-
matolactotroph (GH3) tumors decreased PRL levels by
88% and attenuated tumor growth by 41%. Kansra et al.
(540) showed similar in vitro results, albeit only in non-
physiological (i.e., estrogen-deprived) conditions. In one
short-term human study of eight patients with giant in-
vasive PRL-secreting pituitary adenomas, tamoxifen given
over 5 d modestly suppressed PRL secretion and had a
slight but significant potentiating effect on bromocriptine-
mediated inhibition of PRL secretion (535). Neither ralox-
ifene nor fulvestrant has been tested in vivo in humans
with prolactinomas.
A second experimental approach aimed at mitigating the
proliferative effects of estrogen on prolactinomas involves
reduction of endogenous estradiol levels through aromatase
inhibition. A single case report describes the ability of anas-
trazole to augment PRL suppression when combined with
very high doses of cabergoline (331). Long-term effects of
aromatase inhibitors are uncertain, however, and chronic
estrogen deficiency may have important adverse conse-
quences on bone (543, 544). Therefore, this therapeutic ap-
proach should be reserved for specific situations that are not
amenable to standard therapy and in particular for those
prolactinomas that show evidence for exquisite sensitivity to
estradiol.
C. Prolactin receptor antagonists
Several PRL receptor antagonists are under development
as potential therapies for the treatment of breast and prostate
cancer (reviewed in Ref. 545). The rationale for PRL receptor
antagonism in this context is to block the proliferative effects
of autocrine-derived PRL on these tissues (546, 547). The PRL
receptor could represent a theoretical target to disrupt the
adverse peripheral effects of hyperprolactinemia due to pro-
lactinoma, and PRL receptor antagonists have been proposed
as potential agents to treat dopamine agonist-resistant pro-
lactinomas (545). However, any effects of PRL receptor an-
tagonism on PRL secretion and cell growth are uncertain—
both in normal and adenomatous human lactotrophs. It
appears that the expression of the PRL receptor is up-regu-
lated in human prolactinomas, but the functional conse-
quences of this alteration are unknown (548, 549). In mice, the
targeted disruption of the PRL receptor results in hyperp-
rolactinemia, lactotroph hyperplasia, and ultimately, pro-
lactinomas (550, 551). Whether a long feedback loop exists in
humans that regulates PRL secretion and cell growth has not
been determined.
D. Gene therapy
Gene therapy represents a potential future therapy for the
treatment of pituitary adenomas, although it remains at an
early stage of investigation. The underlying concepts of gene
therapy and a summary of preclinical studies in pituitary
tissue and adenomas are the subject of several recent reviews,
to which the reader is referred for further information (552–
554). In view of the fact that most prolactinomas are benign
microadenomas that are successfully and safely treated with
available medical or surgical methods, and that sustained
hyperprolactinemia is not associated with mortality, as hor-
monal hypersecretion is for other pituitary tumor subtypes,
the gene therapy approach will have limited applicability for
the majority of these tumors. However, gene therapy could
play a role in the treatment of large aggressive prolactino-
mas, locally invasive postsurgical residual disease, or pitu-
itary carcinomas (555).
Most preclinical gene therapy models for the treatment of
pituitary adenomas have used adenoviral vectors as the de-
livery system because of their high efficiency in infecting
nondividing cells (556). A number of different strategies have
been attempted to ablate pituitary tumors by varying the
therapeutic gene delivered. These therapeutic genes fall into
the following categories: suicide gene/prodrugs, toxins, tu-
mor suppressors, apoptosis inhibitors, growth inhibitors,
and inhibitors of specific signaling pathways. Equally im-
portant to the success of gene therapy are the achievement
of cell-type specificity for transgene delivery and the ability
to regulate transgene expression. Targeting strategies have
taken advantage of the highly specialized profile of tran-
scription factors, hormones, and receptors to specifically tar-
get a particular pituitary cell type. Cell type specificity for
transgene delivery has already been achieved by placing
transgenes under the control of cell-specific promoters (i.e.,
the human PRL promoter). Regulation of transgene expres-
sion is at an earlier stage of investigation, but some initial
studies have shown that expression of the therapeutic gene
can be temporally or situationally regulated (557–559).
A number of preclinical in vivo models of gene therapy
have been designed that specifically target lactotroph ade-
nomas. Many of these models are based upon the method of
gene-directed enzyme prodrug therapy in which the gene
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encoding thymidine kinase (TK) is delivered to tumor cells,
followed by the systemic administration of a nucleoside an-
alog such as gancyclovir, which is converted locally to a
cytotoxin by TK (560, 561). In applications of gene therapy
targeting prolactinomas, the gene encoding TK is placed
under the control of the human PRL (or cytomegalovirus)
promoter (562–564). Other models have used adenovirus to
overexpress genes encoding tyrosine hydroxylase (559) or a
dominant-negative ER (565) with the goal of inhibiting
growth of sc lactotroph tumors in mice. Together, these mod-
els have demonstrated the feasibility of preventing tumor
growth, reducing tumor mass, and attenuating hyperpro-
lactinemia using gene therapy approaches. Nevertheless, it
appears that systemic injection of adenoviral vectors carry-
ing cell-specific therapeutic genes may not be able to generate
high enough transgene expression in the pituitary to be ef-
ficacious. Systemic administration of adenoviral vector is
only effective using strong viral promoters that are accom-
panied by ubiquitous expression; adenoviral constructs us-
ing cell-specific promoters have thus far required direct ste-
reotaxic intrapituitary injection. Therefore, at the present
time, only direct surgical approaches using injection into the
body of the tumor or tumor remnant appear imminently
feasible (555). A number of additional issues will need to be
addressed before gene therapy becomes a reality, including
the development of safer and more effective gene delivery
vectors, the refinement of strategies to regulate transgene
expression, and the identification of specific gene targets that
do not require a high rate of proliferation to induce cell death.
E. Nerve growth factor
NGF has been proposed as potential redifferentiation ther-
apy for the treatment of dopamine agonist-resistant prolacti-
nomas lacking D2 receptor expression (see Section VII.B). The
inspiration for this therapy is based upon previous in vitro
studies demonstrating the effectiveness of NGF in restoring
D2 receptor expression, reducing tumor proliferation, and
abolishing the tumorigenicity of dopamine-resistant pro-
lactinoma cells that were implanted sc into mice (298, 314,
315, 566).
The therapeutic use of recombinant NGF has been ex-
plored in other areas, including the treatment of diabetic
polyneuropathy and HIV-related neuropathy (567, 568).
However, clinical application of nerve growth treatment in
humans has been limited due to challenging issues related to
the safe and effective delivery of NGF to the tissue of interest.
NGF does not cross the blood-brain barrier when adminis-
tered peripherally and can cause intolerable and unaccept-
able side effects at high doses (568, 569). Recently, NGF
therapy was investigated in a phase 1 trial of NGF gene
delivery for Alzheimer’s disease, wherein autologous fibro-
blasts genetically modified to express human NGF were ste-
reotaxically implanted into the forebrain (570). In this trial,
long-term adverse effects of NGF were not observed after a
mean follow-up of 22 months. Pending further verification of
NGF efficacy and the development of safe, effective, and
acceptable gene delivery systems for the treatment of pitu-
itary tumors, NGF may represent a potential means of red-
ifferentiating therapy in highly selected cases.
TABLE 14. Genetic alterations identified in human prolactinomasa
Gene Protein Identified defect Human tumors Animal model Ref.
Gain of function
events
CCND1 Cyclin D1 Overexpression Aggressive adenomas NA 603
RAS Ras Somatic mutation Pituitary carcinomas NA 604–607
PTTG1 Pituitary tumor-
transforming protein 1
Overexpression All classes of pituitary
adenomas
Multipotential focal
hyperplasia3
adenomas (LH, FSH,
TSH, under control of
subunit promoter)
606, 607
FGFR4 Truncated ptd-FGF4
receptor
Alternative transcriptional
initiation
All classes of pituitary
adenomas
Lactotroph adenomas
(under control of the
PRL promoter)
608–610
HMGA2 High mobility group AT-
hook 2
Gene amplification3
HMGA2 overexpression
Prolactinomas Somatolactotroph
adenomas
611, 612
BMP4 Bone morphogenetic
protein 4
Overexpression Prolactinomas Lactotroph adenomasb 613
5delER Truncated ER Alternative splice variant Prolactinomas NA 527, 614
Loss of function
events
MEN1 Menin Inactivating germline
mutation followed by
somatic mutation
All (prolactinomas most
common)
Adenomas 615
RB1 Retinoblastoma Promoter methylation Aggressive adenomas Intermediate lobe
hyperplasia3
adenomas
616, 617
CDKN2A INK4a (p16) Promoter methylation Adenomas KO: sarcomas,
lymphomas,
melanoma
618–620
DRD2 Dopamine receptor D2 Decreased expression DA resistant
prolactinomas
Lactotroph hyperplasia
3 adenomas
621, 622
NA, Not applicable; FGF, fibroblast growth factor; KO, knockout.
a Only genetic defects for which there is experimental evidence that the defects are also identified in human prolactinomas are listed.
b BMP4 is overexpressed in prolactinomas derived from dopamine D2 receptor-deficient female mice.
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F. Molecular therapeutics
Recent advances in the understanding of signaling path-
ways controlling pituitary hormone production and in the
delineation of underlying molecular defects involved in pi-
tuitary tumorigenesis have provided a source of potential
therapeutic targets for the treatment of pituitary tumors that
are not responsive to standard therapy (571, 572). Several
candidate factors have been implicated in the pathogenesis
and progression of prolactinomas (Tables 14 and 15). The
discovery of these genetic alterations may offer the oppor-
tunity to develop highly targeted and effective therapeutic
approaches that are directed at processes fundamentally in-
volved in tumorigenesis.
The concept of molecular therapeutics aims at developing
treatments that modulate a specific factor or cellular pathway
thought to play a critical role in the survival, proliferation, or
invasion of a tumorous cell (573). Although there are many
genetic aberrations that can be identified in pituitary ade-
nomas, only a subset of these are critically involved in cell
proliferation, cell survival, and tumor progression. One of
the challenges for the development of successful targeted
therapy will be the ability to distinguish which genetic al-
terations are truly pathogenetic from those that are epiphe-
nomena that arise secondarily, accompanying the process of
tumorigenesis (294, 574). Thus, validation that a proposed
genetic aberration has tumorigenic causality using stringent
criteria with multiple lines of scientific evidence is essential
for the selection of “critical targets” (575). Although it re-
mains to be proven as a general principle, most authorities
believe that interference with tumor-initiating events will
ultimately be necessary for effective targeted therapy (573,
576). The optimal implementation of this type of approach
will require the development of molecular diagnostic mark-
ers able to identify patients with tumors whose growth is
governed by the chosen therapy. Although this area of in-
vestigation remains in the very early stages of discovery, the
promise of these technologies may lead to a new era of
individualized molecular medicine, wherein each patient is
treated on the basis of the underlying genetic aberrations,
resulting in more effective and less toxic therapy (577).
XIII. Concluding Remarks
In the present era, most prolactinomas are successfully
treated with medical therapy with minimal morbidity. The
extraordinary response of these tumors to medical therapy
represents one of the most remarkable and satisfying
achievements in the field of endocrinology. However, the
small proportion of prolactinomas that are unresponsive to
dopamine agonists represent the most severe aspect of this
disease and unfortunately, are often associated with poor
response to nonmedical approaches, including transsphe-
noidal surgery and radiotherapy. For these patients, a com-
bination of medical, neurosurgical, and radiation therapies
may be necessary to control tumor growth. Investigative ther-
apies targeting underlying molecular defects involved in the
pathogenesis of these tumors hold promise for devising strat-
egies to treat prolactinomas that remain therapeutic challenges.
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